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Nowhere  in  these  ancient  communities  of  the  Eurasian  land mass, where  it  is  so 
common and  feared,  is  there a  record of  its beginning. Throughout history,  it had 
always  been  there,  a  familiar  evil,  yet  forever  changing,  formless,  unknowable. 
Where other epidemics might last weeks or months, where even the bubonic plague 
would  be  marked  forever  afterwards  by  the  year  it  reigned,  the  epidemics  of 
tuberculosis would last whole centuries and even multiples of centuries. Tuberculosis 
rose  slowly,  silently,  seeping  into  homes  of millions,  like  an  ageless miasma. And 
once  arrived,  it  never went  away  again.  Year  after  year,  century  after  century,  it 
tightened  its  relentless  hold,  worsening  whenever  war  or  famine  reduced  the 
peoples'  resistance,  infecting  virtually  everybody,  inexplicably  sparing  some  while 
destroying  others,  bringing  the  young  down  onto  their  sickbeds,  where  the  flesh 
slowly  fell  from  their bones and  they were consumed  in  the years  long  fever,  their 
minds brilliantly alert until, in apocalyptic numbers, they died, like the fallen leaves of 
a dreadful and premature autumn. 
 
                                           The Forgotten Plague: 
How the War against Tuberculosis was Won ‐ and Lost 
Frank Ryan, 1992 
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ABSTRACT 
Background: Infection by tuberculosis and multidrug resistance 
are increasing in Sudan as in many other countries. Little data are 
available about diversity of drug resistant Mycobacterium 
tuberculosis.  
Objectives: This study aimed to determine the drug resistance 
patterns of Mycobacterium tuberculosis from different regions of 
Sudan, to study the genetic diversity of drug resistant 
Mycobacterium tuberculosis and to determine the phylogenetic 
relation of resistant isolates. 
Methods:  A cross sectional study was conducted during the period 
June 2008 - June 2010, in nine states of Sudan (Khartoum, Kassala, 
Gadarif, Gezera, Damazeen, Northern and Southern Sudan, 
Kordofan and Darfur). The technical work was done at National 
Health Laboratory and Institute of Endemic Diseases.  Sputum 
samples were collected from 420 pulmonary tuberculosis patients, 
the patients were consented and fully interviewed. Indirect Ziehl’s- 
 
 
Neelsen  stain and inoculation onto LJ medium were done. 
Biochemical tests and Polymerase chain reaction technique were 
used for characterization of the isolates. In vitro drug sensitivity 
(proportion method) to the first line anti- tuberculous drugs was 
done for all isolates. Single step nested PCR and DNA sequencing 
was done for the resistant strains to determine the diversity of drug 
resistant isolates.  Phylogenetic analysis was used to determine the 
genetic relation of the drug resistant isolates. 
Results:  The Acid Fast Bacilli smear positive was 94%. Two 
hundred and forty two samples were successfully grown on LJ 
media. Biochemical and molecular methods identified 99.2% as 
Mycobacterium tuberculosis complex and 0.8% as Mycobacteria 
other than Mycobacterium tuberculosis, which were further 
characterized as M. kansassi and M. avium. On in-vitro drug 
sensitivity, 48 were resistant isolates; (14.2% were resistant to 
Rifampcin, 11.3% to Isoniazid, 10% to Streptomycin and 7.08% to 
Ethambutol). Four isolates were multi-resistant to the four above 
mentioned drugs. M. kansassi was resistant to INH and to RIF. 
Sequencing of the PCR amplified rpoB gene of 28 randomly 
selected resistant MTBC isolates showed mutations in 9 isolates. 
One isolate from Kassala had double mutation at codon 516 (GAC 
 
 
→ GAA/ Asp →Glu) and codon 526 (CAC→AAC/ His → Asn).  
One MDR strain from Khartoum North had mutation at codon 516 
(GAC→ GTC/ Asp → Val), three MDR strains had harboured the 
CAC variant at codon 526; one isolate had the CTC mutation at 
this codon and the other CGC, the third one had the mutant type 
GAC genotype at the same site. Four isolates; from Kassala, 
Gadarif, Damazeen and Southern Sudan had single mutation at 
codon 531(TTG→ TGG/ Ser→ Leu).  Phylogenetic analysis 
clustered the resistant isolates into five major clusters.   
Conclusion: The drug resistance rate was 20% and multidrug 
resistant was 7.5%, however, this result was the first to represent 
the national resistance rate which is alarming. Isolates from 
Kassala showed the highest drug resistance rate (49.1%) while, 
Khartoum showed the highest multidrug resistant rate (2.9%). High 
prevalence of resistance to rifampicin was associated with various 
point mutations in the 81-bp core region of the rpoB gene. The 
phylogenetic analysis showed strong relationship between the 
Mycobacterium tuberculosis resistant strains in Sudan, suggesting 
a common source of resistance. 
  
 
 
 
 
 
  اﻟﻤﺴﺘﺨﻠﺺ 
اﻟﻤﻘﺎوﻣﺔ ﻟﻌﺪة ﻋﻘﺎﻗﻴﺮ  زاد اﻧﺘﺸﺎر ﻣﺮض اﻟﺴﻞ و اﻹﺻﺎﺑﺔ ﺑﻌﺘﺮات اﻟﺴﻞ:  اﻟﻤﻘـﺪﻣﺔ 
ﻻ ﺗﺘﻮﻓﺮ  ﻣﻌﻠﻮﻣﺎت آﺜﻴﺮة ﺣﻮل . اﻟﺴﻮدان آﻤﺎ ﻓﻲ اﻟﻌﺪﻳﺪ ﻣﻦ اﻟﺪول اﻷﺧﺮىﻓﻲ  ًاﻣﺆﺧﺮ
 .اﻟﺘﻨﻮع اﻟﺠﻴﻨﻲ ﻟﻌﺘﺮات اﻟﺴﻞ اﻟﻤﻘﺎوﻣﺔ ﻟﻠﻌﻼج 
ﻟﺘﺤﺪﻳﺪ  ﻤﺘﻔﻄﺮة اﻟﺴﻠﻴﺔ ﻟﻠﻌﻼج واﻟ ﻣﻘﺎوﻣﺔأﻧﻤﺎط ﺗﻬﺪف هﺬﻩ اﻟﺪراﺳﺔ ﻟﻤﻌﺮﻓﺔ   : اﻷهﺪاف
ﻟﻬﺬﻩ اﻷﻧﻤﺎط اﻟﻤﻌﺰوﻟﺔ ﻣﻦ اﻟﻌﻼﻗﺔ اﻟﺨﺎﺻﺔ ﺑﺎﻟﻤﻨﺸﺄ اﻟﻨﻮﻋﻲ  اﻟﺘﻨﻮع اﻟﺠﻴﻨﻲ و ﻟﺘﻮﺿﻴﺢ
  .اﻟﺴﻮدان ﻣﻦﻣﺨﺘﻠﻔﺔ  وﻻﻳﺎت ﻓﻰﻣﺮﺿﻰ اﻟﺴﻞ اﻟﺮﺋﻮي 
، م 0102ﻰ ﻳﻮﻧﻴﻮ م إﻟ 8002ﻓﻲ اﻟﻔﺘﺮة ﻣﻦ ﻳﻮﻧﻴﻮ  ﻤﻘﻄﻌﻴﺔاﻟأﺟﺮﻳﺖ هﺬﻩ اﻟﺪراﺳﺔ   :اﻟﻄﺮق
ﺸﻤﺎﻟﻴﺔ اﻟ ،اﻟﺪﻣﺎزﻳﻦ ،اﻟﺠﺰﻳﺮة ،اﻟﻘﻀﺎرفاﻟﺨﺮﻃﻮم، آﺴﻼ، ) اﻟﺴﻮدان وﻻﻳﺎتﻓﻲ ﺗﺴﻊ ﻣﻦ 
اﻟﺠﺰء اﻟﻌﻤﻠﻲ اﻟﺘﻘﻨﻲ أﺟﺮى ﻓﻲ آﻞ ﻣﻦ اﻟﻤﻌﻤﻞ اﻟﻘﻮﻣﻲ  .(اﻟﺠﻨﻮب، آﺮدﻓﺎن و دارﻓﻮر ،
ﺳﻞ ﻣﺮﺿﻰ  ﻣﻦ ( ﺑﻠﻐﻢ)ﺗﻔﺎف   ﻋﻴﻨﺔ 024ﺗﻢ ﺟﻤﻊ . اﻟﺼﺤﻲ و ﻣﻌﻬﺪ اﻷﻣﺮاض اﻟﻤﺘﻮﻃﻨﺔ
. ﻻﺳﺘﺒﻴﺎن اﻟﺨﺎص ﺑﺎﻟﺪراﺳﺔﻣﻮﺟﺒﻲ اﻟﻠﻄﺎﺧﺔ ﺑﻌﺪ ﻣﻮاﻓﻘﺘﻬﻢ اﻟﻄﻮﻋﻴﺔ  وﻣﻞء ارﺋﻮي 
ﻟﺼﺒﻐﺔ زﻳﻞ ﻤﺒﺎﺷﺮة اﻟأﺧﻀﻌﺖ ﻋﻴﻨﺎت اﻟﺘﻔﺎف ﻟﻠﻔﺤﺺ أﻟﻤﺠﻬﺮي ﺑﺎﺳﺘﺨﺪام اﻟﻄﺮﻳﻘﺔ ﻏﻴﺮ 
 و ﺤﻴﻮﻳﺔ ء اﻟﻜﻴﻤﻴﺎاﻟأﺟﺮﻳﺖ اﺧﺘﺒﺎرات  .ﺒﺎﺗﻬﺎ ﻓﻲ وﺳﺎﺋﻂ ﻟﻮﻧﺸﺘﺎﻳﻦ  ﺟﻴﻨﺴﻦﻧﻴﻠﺴﻮن وﺗﻢ اﺳﺘﻨ
أﺟﺮى اﺧﺘﺒﺎر . ﺑﻐﺮض ﺗﻤﻴﻴﺰ اﻷﻧﻤﺎط اﻟﻤﻌﺰوﻟﺔ اﺧﺘﺒﺎر اﻟﺘﻔﺎﻋﻞ اﻟﺴﻠﺴﻠﻰ اﻟﺒﻠﻤﺮى
 ،اﻟﺮﻳﻔﺎﻣﺒﺴﻴﻦ)ﻣﺮض اﻟﺴﻞ  ﻻدوﻳﺔ ﻋﻼجاﻟﺤﺴﺎﺳﻴﺔ ﻟﻤﻌﺮﻓﺔ ﻣﻘﺎوﻣﺔ هﺬﻩ اﻟﻌﺼﻴﺎت اﻟﺴﻠﻴﺔ 
 
 
وآﺬﻟﻚ أﺟﺮى اﺧﺘﺒﺎر ﺗﺤﻠﻴﻞ ﺳﻼﺳﻞ ( ﻻﺳﺘﺮﺑﺘﻮﻣﺎﻳﺴﻴﻦ و اﻻﻳﺜﺎﻣﺒﻴﺘﻮل ا ،اﻻﻳﺰوﻧﻴﺎزﻳﺪ
ﻲ ﻴﻨاﻟﺘﻨﻮع اﻟﺠ ﻟﻤﻌﺮﻓﺔ ﻋﻼﻗﺔ اﻟﻌﺸﻰ و اﻟﺘﻔﺎﻋﻞ اﻟﺴﻠﺴﻠﻰ اﻟﺒﻠﻤﺮىاﻟﺤﻤﺾ اﻟﻨﻮوي 
  .  ﻟﻠﻤﻌﺰوﻻت اﻟﻤﻘﺎوﻣﺔ ﻟﻠﻌﻼج
ﺗﻤﻜﻨﺖ .  ﻣﻮﺟﺒﺔ اﻟﻠﻄﺎﺧﺔ%(  1.49)أن أﺛﺒﺖ اﻟﻔﺤﺺ أﻟﻤﺠﻬﺮي ﻏﻴﺮ اﻟﻤﺒﺎﺷﺮ   : اﻟﻨﺘﺎﺋﺞ
ﺣﻴﻮﻳﺔ واﺧﺘﺒﺎر  ﺧﺘﺒﺎرات اﻟﻜﻴﻤﻴﺎاﻻ. ﻓﻲ ﻣﺴﺘﻨﺒﺘﺎت  ﻟﻮﻧﺸﺘﺎﻳﻦ  ﺟﻴﻨﺴﻦ ﻮﻋﻴﻨﺔ ﻣﻦ اﻟﻨﻤ 242
ﻣﺘﻔﻄﺮة %  8.0ﻣﺘﻔﻄﺮة  ﺳﻠﻴﻪ وأن  %  2.99أن   ﺖﺗﺤﻠﻴﻞ ﺳﻼﺳﻞ اﻟﺤﻤﺾ اﻟﻨﻮوي اﺛﺒﺘ
اﺟﺮي  . .muiva .M و   issasnaK .M   ﺑﺄﻧﻬﻤﺎ ﻣﺘﻔﻄﺮﺗﻰ ﻏﻴﺮ ﺳﻠﻴﻪ ﺻﻨﻔﺖ ﻻﺣﻘﺎ
ﻋﺘﺮﻩ ﻣﻘﺎوﻣﺔ  042/84 أن اﺧﺘﺒﺎر اﻟﺤﺴﺎﺳﻴﺔ ﻟﻠﻤﻀﺎدات اﻟﺴﻠﻴﺔ وﻗﺪ اﺛﺒﺖ اﻻﺧﺘﺒﺎر
 % 2.41ﻧﺴﺒﺔ ﻣﻘﺎوﻣﺔ ﻟﻠﺮﻳﻔﺎﻣﺒﺴﻴﻦ  ﻟﻠﻌﻘﺎرات اﻟﻤﺴﺘﺨﺪﻣﺔ ﻟﻌﻼج اﻟﺴﻞ وﻟﻘﺪ ﺳﺠﻠﺖ أﻋﻠﻰ
وﻟﻘﺪ وﺟﺪ أن   .%1.7ﺎﻧﺒﺘﻮل ﺛﻢ اﻻﻳﺜ%  01 ﻓﺎﻻﺳﺘﺮﺑﺘﻮﻣﺎﺳﻴﻦ%  3.11ﻳﻠﻴﻪ اﻻﻳﺰوﻧﻴﺎزﻳﺪ 
ﻣﻌﺰوﻟﺔ ﻣﺘﻌﺪدة  81 )%5.7(رﺑﻌﺔ اﻟﻤﺬآﻮرة أﻋﻼﻩ و اﻷ دوﻳﺔﻟﻸأرﺑﻌﺔ ﻋﺘﺮات ﻣﻘﺎوﻣﺔ 
 .ﻣﻘﺎوﻣﺔ ﻟﻌﻘﺎري اﻟﺮﻳﻔﺎﻣﺒﺴﻴﻦ و اﻻﻳﺰوﻧﻴﺎزﻳﺪ issasnaK .Mوﺟﺪ أن . اﻟﻤﻘﺎوﻣﺔ ﻟﻠﻌﻘﺎرات
اﻟﻤﺘﻌﻠﻖ ﺑﻤﻘﺎوﻣﺔ ﻋﻘﺎر   Boprﻟﻔﺤﺺ اﻟﺠﻴﻦ ﻋﺸﻮاﺋﻴﺎ ﻣﻘﺎوﻣﺔ ﻟﻸدوﻳﺔ   ﻋﺘﺮة 82أﺧﻀﻌﺖ 
ﻞ اﻟﺤﻤﺾ اﻟﻨﻮوي ﺑﺎﺳﺘﺨﺪام  اﺧﺘﺒﺎر ﺗﺤﻠﻴﻞ ﺳﻼﺳ اﻟﺮﻳﻔﺎﻣﺒﺴﻴﻦ ﻟﻠﺘﺤﻘﻖ ﻣﻦ وﺟﻮد ﻃﻔﺮة
ﻣﻦ اﻟﻌﺘﺮات  اﻟﻤﻘﺎوﻣﺔ ﺗﺤﻮى ﺗﻐﻴﺮات ﻓﻲ اﻟﻤﻨﻄﻘﺔ اﻟﻤﺤﺪدة ﻟﻤﻘﺎوﻣﺔ   ووﺟﺪ أن ﺗﺴﻊ
آﺴﻼ وﻻﻳﺔ اﺣﺘﻮت ﻋﺘﺮﻩ واﺣﺪة ﻣﻦ اﻟﻌﺘﺮات اﻟﻤﻌﺰوﻟﺔ ﻣﻦ .  )RDRR(اﻟﺮﻳﻔﺎﻣﺒﺴﻴﻦ 
  625و   615 )ulG→ psA /AAG → CAG(  : ﻃﻔﺮﺗﻴﻦ ﻓﻲ اﻟﻤﻮﻗﻌﻴﻦ ﻋﻠﻲ
ى وﻋﺘﺮﻩ ﻣﺘﻌﺪدة اﻟﻤﻘﺎوﻣﺔ ﻣﻦ اﻟﺨﺮﻃﻮم ﺑﺤﺮي ﺗﺤﻮ )nsA → siH /CAA→CAC(
وﺛﻼث ﻋﺘﺮات ﻣﺘﻌﺪدة . )laV → psA /CTG →CAG( 615ﻓﻲ اﻟﻤﻮﻗﻊ  ﻃﻔﺮة
 CAC  ﻟﻞ    ﺔﻣﺨﺘﻠﻔ ﻃﻔﺮاتﻣﻦ  اﻣﺪرﻣﺎن  وﻋﺘﺮﺗﻴﻦ ﻣﻦ آﺴﻼ   ﺗﺤﻮى اﺣﺪاهﺎ اﻟﻤﻘﺎوﻣﺔ  
  :آﺎﻻﺗﻰ ﻋﻠﻲ اﻟﺘﻮاﻟﻲ   625ﻓﻲ اﻟﻤﻮﻗﻊ  
 
 
 CAC ,grA→ siH / CGC→ CAC ,ueL → siH / CTC → CAC(
 ﻋﺘﺮات  ﻓﻰ آﻞ ﻣﻦ اﻟﻘﻀﺎرف ، آﺴﻼ ، 4وﻟﻘﺪ وﺟﺪ أن (   psA → siH /CAG→
 reS /GTT → GCT) 135و ﺟﻨﻮب اﻟﺴﻮدان أﻇﻬﺮت ﺗﻐﻴﺮا ﻓﻲ اﻟﻤﻨﻄﻘﺔ   اﻟﺪﻣﺎزﻳﻦ
اﻟﻨﻮﻋﻲ  ﺄﻨﺸﻤاﻟﺨﺎص ﺑﺎﻟ اﻟﺘﺤﻠﻴﻞ  .رﺑﻌﺔ ﺳﺎﺑﻘﺔ اﻟﺬآﺮ اﻷ دوﻳﺔﻟﻸوهﻰ ﻣﻘﺎوﻣﺔ (   ueL →
  .ﻟﻌﺘﺮات اﻟﻤﻘﺎوﻣﺔ ﻟﻠﻌﻼج إﻟﻰ ﺧﻤﺲ ﻣﺠﻤﻮﻋﺎت رﺋﻴﺴﻴﺔﻗﺴﻢ ا
ﻩ اﻟﺪراﺳﺔ ﺣﻠﻠﺖ ﻋﺼﻴﺎت اﻟﺴﻞ ﻣﻦ ﺗﺴﻊ وﻻﻳﺎت ﻓﻲ اﻟﺴﻮدان، ووﺟﺪت أن ﺬه:   اﻟﺨﻼﺻﺔ
اﻟﻌﺘﺮات اﻟﻤﻌﺰوﻟﺔ ﻣﻦ آﺴﻼ أﻇﻬﺮت أﻋﻠﻰ ﻧﺴﺒﺔ ﻣﻘﺎوﻣﺔ %.  02ﻧﺴﺒﺔ اﻟﻌﺘﺮات اﻟﻤﻘﺎوﻣﺔ 
ﺑﻴﻨﻤﺎ أﻇﻬﺮت اﻟﻌﺘﺮات اﻟﻤﻌﺰوﻟﺔ ﻣﻦ اﻟﺨﺮﻃﻮم اﻋﻠﻲ ﻧﺴﺒﺔ ﻣﻘﺎوﻣﺔ %(  1.94)ﻟﻸدوﻳﺔ 
ﺒﺮ اﻷوﻟﻲ اﻟﺘﻲ ﺗﻤﺜﻞ اﻟﻨﺴﺒﺔ اﻟﻘﻮﻣﻴﺔ ﻟﻤﻘﺎوﻣﺔ ﻩ اﻟﻨﺘﺎﺋﺞ ﺗﻌﺘﺬه%(. 9.2 )ﻣﺘﻌﺪدة ﻟﻸدوﻳﺔ 
أﻇﻬﺮت اﻟﺪراﺳﺔ ﻧﺴﺒﺔ ﻣﻘﺎوﻣﺔ ﻋﺎﻟﻴﺔ  .اﻟﺴﻞﻋﺘﺮات اﻟﺴﻞ ﻟﻸدوﻳﺔ اﻟﻤﺴﺘﻌﻤﻠﺔ ﻟﻌﻼج ﻣﺮض 
اﻟﺠﻮهﺮﻳﺔ ( pb 18) ﻟﻌﻘﺎر اﻟﺮﻳﻔﺎﻣﺒﺴﻴﻦ ﻣﺮﺗﺒﻄﺔ ﺑﻄﻔﺮات  ﻋﻨﺪ  ﻧﻘﺎط ﻣﺘﻌﺪدة  ﻓﻲ اﻟﻤﻨﻄﻘﺔ
اﻟﻨﻮﻋﻲ وﺟﻮد ﻋﻼﻗﺔ وﻃﻴﺪة ﺑﻴﻦ ﻣﺨﺘﻠﻒ اﻟﻌﺘﺮات   أﻇﻬﺮ ﺗﺤﻠﻴﻞ اﻟﻨﺸﻮء.  Boprﻟﻠﺠﻴﻦ  
  .  ﻬﺬﻩ اﻟﻤﻘﺎوﻣﺔﻟﻟﻠﻌﻼج ﻓﻲ اﻟﺴﻮدان ﻣﻤﺎ ﻳﺸﻴﺮ إﻟﻲ وﺟﻮد ﻣﺼﺪر ﻣﺸﺘﺮك  اﻟﻤﻘﺎوﻣﺔ
   
   
 
 
 
 
 
 
 
 
 
 
  
  
                               
  
 
 
 
1 
 
Chapter one 
Introduction and Literature Review  
Introduction 
Tuberculosis (TB) has a long history. It was present before the 
beginning of recorded history and has left its mark on human 
creativity, music, art, and literature; and has influenced the advance of 
biomedical sciences and healthcare. Its causative agent 
Mycobacterium tuberculosis may have killed more persons than any 
other microbial pathogen (Daniel 2006). 
It is presumed that the genus Mycobacterium originated more 
than 150 million years ago (Daniel 2006). An early progenitor of M. 
tuberculosis was probably contemporaneous and co-evolved with 
early hominids in East Africa, three million years ago. The modern 
members of M. tuberculosis complex seem to have originated from a 
common progenitor about 15,000- 35,000 years ago (Gutierrez et al 
2005). 
TB was documented in Egypt, India, and China as early as 
5,000, 3,300, and 2,300 years ago, respectively (Daniel 2006). Typical 
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skeletal abnormalities, including Pott’s deformities, were found in 
Egyptian and Indian mummies and were also depicted in early 
Egyptian and pre-Colombian art Identification of genetic material 
from M. tuberculosis in ancient tissues has provided a powerful tool 
for the investigation of the incidence and spread of human TB in 
historic periods. It also offers potential new insights into the 
molecular evolution and global distribution of these microbes. 
TB is an ancient disease with a wide geographical distribution. 
The disease was widespread in Egypt and Rome (Zink et al 2003, 
Donoghue et al 2004); it existed in America before Columbus (Salo et 
al 1994, Konomi et al 2002, Sotomayor et al 2004), and in Borneo 
before any European contact (Donoghue et al 2004). The earliest 
DNA-based documentation of the presence of Mycobacterium 
tuberculosis complex (MTBC) organisms was accomplished in a 
subchondral articular surface from an extinct long-horned Pleistocene 
bison from Wyoming, US, which was radiocarbon-dated at 17,870 +/- 
230 years before the present (Rothschild et al 2001). Another importa- 
nt achievement of the studies on ancient DNA was the confirmation of 
the TB diagnosis in human remains that showed the typical pathology. 
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Mycobacterial DNA was detected in bone lesions in the spine of a 
male human skeleton from the Iron Age (400-230 BC), found in 
Dorset, United Kingdom (Taylor et al 2005); skin samples from the 
pelvic region of Andean mummies, carbon-dated from 140 to 1,200 
AD (Konomi et al 2002); and calcified pleura from 1,400 year-old 
remains, found in a Byzantine basilica in the Negev desert (Donoghue 
et al 1998). DNA techniques have also shown the presence of 
mycobacterial DNA, at a lower frequency, in bones with no 
pathological changes, suggesting either dissemination of the TB 
bacilli immediately prior to death or chronic milliary TB (Zink et al 
2003). Molecular methods other than PCR have also been used to 
demonstrate the presence of the tubercle bacillus in ancient remains, 
including mycolic acid analysis by high performance liquid 
chromatography (HPLC), which is used for authentication of positive 
PCR findings in calcified pleura remains (Donoghue et al 1998). 
Spoligotyping is a PCR-based technique used for identification and 
typing of M. tuberculosis complex bacteria. It is a valuable tool for the 
study of archeological material, especially when the DNA is highly 
fragmented, because fragments as small as 55-60 bp long are 
sufficient to provide a positive result (Donoghue et al 2004). 
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Spoligotyping was the method used to study the Plesitocene remains 
of a bison (Rothschild et al 2001) and was also applied to a subculture 
of the original tubercle bacillus isolated by Robert Koch, confirming 
its species identification as M. tuberculosis rather than 
Mycobacterium bovis (Taylor et al 2003). 
Tuberculosis is primarily a disease of the lungs and the 
infection is contracted by inhalation of infectious aerosols. The most 
infectious cases are those with a positive smear by microscopy.  
Active pulmonary tuberculosis presents as fatigue, anorexia, loss of 
weight, low-grade fever, night sweats, chronic cough, and 
haemoptysis. (WHO 2004, Metchock et al 1995) . 
One third of the world’s population (about 2 billion people) is 
estimated to be infected with the tubercle bacillus, but a few (5-10%) 
develop active tuberculosis. Globally, there are eight million new 
cases of tuberculosis per annum and three million people die from the 
disease annually (Raviglione et al 1995). Approximately two thirds of 
the world’s cases occur in Asian countries, but the disease is also 
endemic in several countries in Africa and other contents (Dye et al 
1999). War and social upheaval have played a role in the spread of 
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tuberculosis beyond endemic zones. The increase in the global burden 
has resulted in the World Health Organization (WHO) in 1993 
declaring tuberculosis a ‘Global emergency’ (Blumberg 1995). 
  TB is usually unevenly distributed within countries. Certain 
groups within societies bear a disproportionately high burden. Groups 
such as AIDS patients, close contacts with TB cases, immigrants, 
medically under-serviced poor populations, alcoholics and 
intravenous drug users, people in long-term care facilities, 
correctional institutions, mental institutions, nursing homes/facilities, 
and other long-term residential facilities, mine workers and homeless 
people carry a higher TB burden (CDC 1990). 
The advent of the HIV/AIDS pandemic has fuelled the spread 
of TB worldwide. Sub- Saharan Africa is the most devastated region 
with close to 70% of its inhabitants co-infected with HIV and TB 
(Harries 1998). Persons co-infected with HIV and TB have an 
increased risk of developing active tuberculosis. The result is an 
increase in TB cases among non-HIV infected persons due to a larger 
pool of source cases in the community (Harries 1998). A disturbing 
issue is that this increase in the incidence that threatens to overwhelm 
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TB control programmes will inevitably be accompanied by a rise in 
drug-resistant TB. The best approach to reduce the increasing TB 
caseload attributable to HIV infection will be to complement the 
Directly Observed Treatment Short-course (DOTS) with DOT-plus 
strategies that will rapidly identify Multi-drug resistant (MDR) strains 
and their susceptibility patterns. The association between TB and the 
human immunodeficiency virus (HIV) infection is threatening to 
overwhelm control programmes globally (Kironde and Bamford 
2002). Mycobacteria are assumed to be better preserved than other 
bacteria due to the resistant lipid-rich cell wall and the high proportion 
of guanine and cytosine in their DNA, which increases its stability. M. 
tuberculosis are found only in the tissues of an infected host, and the 
characteristic pathology induced by this strictly mammalian pathogen 
tends to show residual microbial DNA contained in localized lesions. 
 Rationale 
Tuberculosis is endemic in Sudan, little information about the burden 
of the disease and its epidemiology is avalable. This is the first study 
to determine the drug resistance patterns and diversity of 
Mycobacterium tuberculosis isolates from different regions of Sudan, 
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and to map the drug resistance patterns of Mycobacterium 
tuberculosis isolates from Pulmonary TB patients.        
Objectives: 
General objectives  
  To determine diversity of the drug resistant Mycobacterium 
tuberculosis isolates from different regions of Sudan.  
Specific objectives  
1- To determine the drug resistance patterns of Mycobacterium 
tuberculosis isolates from different regions of Sudan.  
2- To study the genetic diversity of drug resistance patterns of 
Mycobacterium tuberculosis isolates from different regions of 
Sudan.  
     3- To determine the phylogenetic relation of resistant strains of 
Mycobacterium tuberculosis isolated from Pulmonary TB 
patients.  
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Litreture Review  
1.1 Historical background 
Tuberculosis (TB) is an infectious disease of humans. Evidence 
of tuberculosis-compatible lesions dates back many thousands of 
years (Salo et al 1994). Viewed from its historical and contemporary 
disease burden perspective, tuberculosis is one of the causes of human 
sufferings. In Europe the mortality ranged between 200 and 300 per 
100 000 of the population at the beginning of the 19th century (Kato-
Maeda et al 2001). The turn for the better came about in the 1880s 
when general living conditions improved and specific TB control and 
public health management measures came into place. Robert Koch 
discovered the causative agent of TB in 1882 (Zumla et al 1999). 
However, treatment of TB with antibiotics had to wait for the 
discovery of streptomycin in 1944 (Chopra and Brennan 1998). In the 
1950s Sir John Crofton and colleagues developed multidrug 
chemotherapy regimens. The subsequent discovery of rifampicin 
permitted the development of the present short course regimens 
(Zumla et al 1999). Tuberculosis has since developed into an 
epidemic fuelled by the human immunodeficiency virus (HIV), non-
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compliance to treatment and poor management of the disease. This 
has resulted in an increase in reactivation rates, re-infection of cured 
patients, and the development of multidrug resistance. 
1.2. Global epidemiology of tuberculosis 
The consequences of TB on society are immense. Worldwide, 
one person out of three is infected with Mycobacterium tuberculosis – 
two billion people in total. TB accounts for 2.5 % of the global burden 
of disease and is the commonest cause of death in young women, 
killing more women than all causes of maternal mortality combined. 
TB currently holds the seventh place in the global ranking of causes of 
death. Unless intensive efforts are made, it is likely to maintain that 
position through to 2020, despite a substantial projected decline in 
disease burden from other infectious diseases (Dye et al 1999, Smith 
2004). 
Effective drugs to treat and cure the disease have been available 
for more than 50 years, yet every 15 seconds, someone in the world 
dies from TB. Even more alarming: a person is newly infected with 
M. tuberculosis every second of every day. Left untreated, a person 
with active TB will infect an average of 10 to 15 other people every 
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year (Dye et al 2005). The human immunodeficiency virus (HIV) 
infection has clearly had a profound effect on TB epidemiology, other 
potentially important risk factors have been somewhat neglected. In 
the coming years, more attention needs to be given to the interaction 
between chronic diseases and TB, including diabetes, undernutrition, 
and respiratory illnesses caused by tobacco and air pollution (Corbett 
et al 2003, WH O 2004). 
In 2010, there were 8.8 million (range, 8.5–9.2 million) incident 
cases of TB, 1.1 million (range, 0.9–1.2 million) deaths from TB 
among HIV-negative people and an additional 0.35 million (range, 
0.32–0.39 million) deaths from HIV-associated TB. There were 3.2 
million (range, 3.0–3.5 million) incident cases of TB and 0.32 million 
(range, 0.20–44 million) deaths from TB among women in 2010 
(WHO 2011). 
In 2010, 6.2 million people were diagnosed with TB and 
notified to national TB control programmes. Of these, 5.4 million had 
TB for the first time and 0.3 million had a recurrent episode of TB 
after being cured of TB in the past. Besides a small number of cases 
whose history of treatment was not recorded, the remaining 0.4 
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million had already been diagnosed with TB but had their treatment 
changed to a retreatment regimen after treatment failed or was 
interrupted. Among people who were diagnosed with TB for the first 
time (new cases), there were 2.6 million cases of sputum smear-
positive pulmonary TB, 2.0 million cases of sputum smear-negative 
pulmonary TB (including cases for which smear status was unknown) 
and 0.8 million cases of extrapulmonary TB, 57% Of the new casesof 
pulmonary TB, were sputum smear-positive (WHO 2011). Between 
1995 and 2010, 55 million TB patients were treated in programmes 
that had adopted the DOTS/Stop TB Strategy, and 46 million were 
successfully treated. These treatments saved almost 7 million lives. 
Alongside these achievements, diagnosis and appropriate treatment of 
multidrug-resistant TB (MDR-TB) remain major challenges. Less 
than 5% of new and previously treated TB patients were tested for 
MDR-TB in most countries in 2010(WHO 2011).  
The reported number of patients enrolled on treatment has 
increased, reaching 46 000 in 2010. However, this was equivalent to 
only 16% of the 290 000 cases of MDR-TB estimated to exist among 
notified TB patients in 2010, globally, equivalent to 128 cases per  
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100 000 population Most of the estimated number ofcases in 
2010 occurred in Asia (59%) and Africa (26%), smaller proportions of 
cases occurred in; the Eastern Mediterranean Region (7%), the 
European Region (5%) and the Region of the Americas (3%). The 22 
TB high burden countries ( HBCs) that have been given highest 
priority at the global level since 2000  accounted for 81%. (WHO 
2011). 
There were an estimated 650 000 cases of MDR-TB among the 
world’s 12.0 million prevalent cases of TB  in the 2010, WHO report 
on global TB control, it was estimated that there were 440 000 
incident cases of MDR-TB in 2008,this includes new and retreatment 
cases (WHO 2011). 
1.3 Distribution of tuberculosis in Sudan  
The poor and under-serviced rural areas, makes Sudan a fertile 
ground for the disease to flourish (El Sony et al 2000). By the end of 
2009 the total number of the finding received by National 
Tuberculosis Control Programme - Sudan (NTBCPS) the new cases 
were 8572, relapses 832, smear negatives 6135, and the extra-
pulmonary 4526, not done 1097, others 76, failure 157 and defaulters 
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702. The case findings by the state by the end of the year 2009 were 
Gadarif 1159, Blue Nile 394, Gezira 2579, Khartoum 7559, kassala 
1546, Kordofan 1950, Darfour 2102, Naher EL Nile 468, Red Sea 
1418, Sinnar 709, White Nile 2107 and Northern State 106 the total 
cases were 22097. (NTBCPS 2009).  The total cases by the end of 
2010 new cases were 7699, relapse 662, failure 145, defaulters 605, 
smear negative 5832, extra-pulmonary 4630 and the total cases were 
20997 (NTBCPS 2010). 
1.4 Tuberculosis and the interaction with the HIV epidemic 
HIV and TB form a lethal combination, each speeding the other’s 
progress. HIV infection is a potent risk factor for TB. Not only does 
HIV increase the risk of reactivating latent M. tuberculosis infection, 
it also increases the risk of rapid TB progression soon after M. 
tuberculosis infection or re-infection. In persons infected with M. 
tuberculosis only, the lifetime risk of developing TB ranges between 
10 % and 20 %. In persons co-infected with M. tuberculosis and HIV, 
however, the annual risk can exceed 10 %. The TB burden in 
countries with a generalized HIV/AIDS epidemic has therefore 
increased rapidly over the past decade, especially in the severely 
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affected countries of eastern and southern Africa. TB is one of the 
most common causes of morbidity and the most common cause of 
death in HIV-positive adults living in less-developed countries, yet it 
is a preventable and treatable disease (Corbett 2003, Aaron 2004, 
WHO 2006b).  It is possible that, in addition to increasing individual 
susceptibility to TB following M. tuberculosis infection, a high 
burden of HIV-associated TB cases also expands M. tuberculosis 
transmission rates at the community level, threatening the health and 
survival of HIV-negative individuals as well. In several countries, 
HIV has been associated with epidemic outbreaks of TB (Corbett 
2003, Aaron 2004, World Health Organization 2006a, WHO 2006b).  
The highest rates of HIV coinfection in TB patients are in the African 
Region, where 44% of TB patients with an HIV test result in 2010 
were HIV-positive (range among high TB/HIV burden countries, 8%–
82%), followed by the Region of the Americas (17%) (WHO 2011). 
In Sudan the total number of TB/HIV in 2010 were 6% (235 out of 
8283 detected case) in nine regions (Khartoum, Kassala, Gadarif, Red 
Sea, River Nile, White nile, N. Kordofan, Sinnar and Gazera) 
(NTBCPS 2010) 
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1.5 Reservoirs of infection 
The incidence of TB varies between the developed and 
developing countries. The distribution of this disease is also uneven 
within countries. Certain groups within societies bear a 
disproportionately high burden. Groups such as AIDS patients, close 
contacts of TB sufferers, immigrants, medically under-serviced poor 
populations, alcoholics and intravenous drug users, people in long-
term care facilities, correctional institutions, mental institutions, 
nursing homes/facilities, and otherlong-term residential facilities, 
mine workers and homeless people carry a higher TB burden (CDC 
1990). 
1.6 Transmission of TB 
Tuberculosis is primarily a disease of the lungs and infection is 
contracted by inhalation of aerosols. When a patient with active 
pulmonary TB coughs or spits, small droplets that contain TB bacilli 
will be produced. Anyone who inhales this air with droplets can then 
be infected and may subsequently develop Tuberculosis. The 
infectiousness of a case of TB is dependent on the concentration of 
TB bacilli within the lungs and their spread into the air surrounding 
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the patient with TB. The most infectious cases are those with a 
positive smear by microscopy (smear positive cases). Extra-
pulmonary cases are almost never infectious, unless their lungs are 
infected as well ( Metchock et al 1995). 
1.7 The presentation and etiology of tuberculosis 
Tuberculosis is characterized by the formation of tubercles and 
tissue necrosis, primarily because of host hypersensitivity and 
inflammation. Infection is usually by inhalation of airborne particles 
and the bacilli spread from the initial location in the lungs to other 
parts of the body via the blood stream, the lymphatic system, and the 
airways or by direct extension to other organs. Primary tuberculosis is 
a mild or asymptomatic local infection. Regional lymph nodes may 
become involved, but in otherwise healthy persons, generalized 
disease does not immediately develop. Organisms in a primary lesion 
remain viable and can become reactivated months or years later to 
initiate secondary tuberculosis. Progression to the secondary stage 
eventually occurs in about 10% of people who have had primary 
tuberculosis (Metchock et al 1995). Reactivated tuberculosis usually 
results in a chronic, spreading lung infection, most often involving the 
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upper lobes. Tubercles develop in involved lung tissue, each 
consisting of a zone of caseation necrosis surrounded by chronic 
inflammatory cells. Pulmonary TB is the infectious and common form 
of the disease, occurring in over 80% of cases. Extra pulmonary 
tuberculosis is a result of the spread of tuberculosis to other organs, 
most commonly pleura, lymph nodes, spine, joints, genito-urinary 
tract, nervous system or abdomen. Tuberculosis may occur in any part 
of the body (Blumberg 1995). Rarely, reactivation results in 
widespread dissemination of tubercles throughout the body (milliary 
tuberculosis). Variant syndromes are caused by organisms of the 
Mycobacterium avium-intracellulare complex, for example, 
tuberculous lymphadenitis in children and severe systemic disease in 
acquired immune deficiency syndrome (AIDS) sufferers (Metchock et 
al 1995). 
Active pulmonary tuberculosis presents as fatigue, anorexia, 
loss of weight, low-grade fever, night sweats, chronic cough, and 
haemoptysis. Local symptoms depend on the parts affected. Active 
pulmonary tuberculosis is relentlessly chronic and, if untreated, leads 
to progressive destruction of lung tissue. Cavities form in the lungs 
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and erosion into pulmonary blood vessels can result in life -
threatening haemorrhage. Gradual deterioration of nutritional status 
and general health culminates in death due to wasting, infection, or 
multiple organ failure (Metchock et al 1995). 
1.8 The causative agent of tuberculosis 
M. tuberculosis complex are the causative agent of tuberculosis, 
the closely related subspecies that form the M. tuberculosis complex 
(MTBC) (The MTBC traditionally consisted of four members: M. 
tuberculosis, M. bovis, M. africanum, and M. microti. More recently, 
three novel species have been described: 
• M. canettii: less virulent than the classical M. tuberculosis H37Rv 
(Fabre 2004). 
• M. caprae: a species that occurs primarily in Spanish goats, and also 
found in humans, in addition M. caprae was isolated from humans 
and wildlife species such as red deer (Prodinger 2002) or wild boar 
(Erler et al   2004, Machackova et al   2004). In Central European 
regions, where M. caprae is the major cause of TB in cattle it is also 
the predominant agent of TB in humans (Kubica et al   2003, 
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Prodinger 2002). In Germany M. bovis subsp. caprae has been descri- 
bed as the causative agent of almost one-third (31 %) of the human M. 
bovis-associated TB cases analyzed (Niemann et al 2002 a). 
•M. pinnipedii: responsible for TB in marine hosts, was first isolated 
from captive and wild sea lions and fur seals from New Zealand and 
Australia (Cousins et al 1993 and 2003).  Many of the isolates 
obtained in Australia, Uruguay, and Argentina have been well 
characterized (Romano et al   1995, Romano et al   1996, Cousins et 
al   1993, Bernardelli et al  1996, Alito et al 1999, Zumarraga et al  
1999a, Zumarraga et al  1999b, Castro Ramos et al  1998). This 
information, together with preliminary tests on seal isolates from 
Great Britain and New Zealand, suggested that the seal bacillus 
(Cousins et al 1993a), isolated from pinnipeds from all continents, 
might be a unique member of the M. tuberculosis complex. The 
results of biochemical tests clearly confirmed that the seal isolates 
belong to the M. tuberculosis complex. M. tuberculosis is the major 
cause of TB, but M. africanum represents up to 60% of cases of TB in 
certain regions in Africa (Zumla et al 1999). Non-tuberculosis 
mycobacteria like M. kansasii and M. avium-intracellulare can also 
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cause pulmonary diseases clinically indistinguishable from 
tuberculosis and are mainly found in patients infected with the human 
immunodeficiency virus (HIV) . 
 1.9 The tubercle bacillus: a continuous taxonomy 
Bacteria of the genus Mycobacterium are non-motile, non-
capsulating thin bacillus and non-sporulated rods. They are grouped in 
the suprageneric rank of actinomycetes that, unusually, have a high 
content (61-71 %) of guanine plus cytosine (G+C) in the genomic 
desoxyribonucleic acid (DNA), and a high lipid content in the wall, 
probably the highest among all bacteria. Several mycolic acids in the 
envelope structure distinguish the mycobacteria. These quirky lipids 
may act as carbon and energy reserves. They are also involved in the 
structure and function of membranes and membranous organelles 
within the cell. However, the above mentioned agents of TB together 
with the vaccine bacilli Calmette-Guérin (BCG) strains rank close to 
each other along a phenotypically continuous taxon (David et al 1978, 
Wayne 1982, Vincent et al   1992, Van Soolingen et al  1997, Van 
Soolingen et al   1998, Niemann et al  2002, Sola 2003, Mostowy et al  
2005). Phenotypic differentiation is consistently clear-cut between the 
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extreme species within the taxon, i.e. M. tuberculosis and M. bovis, 
but differences between species comprised within these two extremes 
are much less defined. The close affiliation among the members of the 
complex is endorsed by high genomic DNA similarity. At the same 
time, some molecular markers allow species differentiation within the 
complex (Niemann et al  2002). 
In general, systematic and clinical mycobacteriologists accept 
new taxa at a slow pace. This is why the taxonomic status of some 
new members of the complex is still uncertain. At the same time, the 
rank and species assignment have been questioned in other cases 
(Niemann et al  2004). The value of phenotypic and genotypic traits in 
the definition of a species in the complex should be reconsidered to 
meet new widely accepted definitions. 
1.10 Genomic organization and genes 
M. tuberculosis H37Rv was revealed to possess a sequence of 
4,411,529 bp, the second largest microbial genome sequenced at that 
time (Cole et al 1998a). The characteristically high guanine plus 
cytosine (G+C content; 65.5 %) was found to be uniform along most 
of the genome, confirming the hypothesis that horizontal gene transfer 
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events are virtually absent in modern M. tuberculosis (Sreevatsan et al 
1997 a, Brosch et al, 2000, Cole and Saint Girons 1994, Kempsell et 
al  1992).   
The most thoroughly studied characteristic of M. tuberculosis is 
the presence and distribution of insertion sequences (IS). Of particular 
interest is IS6110, a sequence of the IS3 family that has been widely 
used for strain typing and molecular epidemiology due to its variation 
in insertion site and copy number (Van Embden et al 1993). Sixteen 
copies of IS6110 were identified in the genome of M. tuberculosis 
H37Rv; some IS6110 insertion sites were clustered in sites named 
insertional hot-spots. The same strain was found to harbor six copies 
of the more stable IS1081, an insertion sequence that yields almost 
identical profiles in most strains when analyzed by Restriction 
Fragment Length Polymorphism (RFLP) (Sola et al 2001, Kanduma 
et al 2003). Another 32 different insertion sequences were found, of 
which seven belonged to the 13E12 family of repetitive sequences; the 
other insertion sequences had not been described in other organisms 
(Cole 1998b). Virtually all the ISs found in M. tuberculosis so far 
belong to previously described IS families (Chandler and Mahillon 
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2002). The only exception is IS1556, which does not fit into any 
known IS family (Cole et al 1999) 
1.11 Chemotherapy and management of TB  
The history of tuberculosis (TB) changed dramatically after the 
introduction of anti mycobacterial agents. Drug treatment is 
fundamental for controlling TB, promoting the cure of the patients 
and breaking the chain of transmission when the anti-tuberculosis 
drug regimen is completely and correctly followed. Anti-tuberculosis 
drug treatment started in 1944, when streptomycin (SM) and para-
amino-salicylic acid (PAS) were discovered. In 1950, the first trial 
was performed comparing the efficacy of SM and PAS both as mono-
therapy or combined. The study demonstrated that combined therapy 
was more effective and resulted in the first multidrug anti-tuberculosis 
treatment that consisted of a long course of both drugs (Palomino 
2007).  In 1952 a third drug, isoniazid (INH), was added to the 
previous combination, greatly improving the efficacy of treatment, but 
which still had to be administered for 18-24 months. In 1960, 
Ethambutol (EMB) substituted PAS, and the treatment course was 
reduced to 18 months. In the ’70s, with the introduction of rifampicin 
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(RIF) into the combination, treatment was shortened to just nine 
months. Finally, in 1980, Pyrazinamide (PZA) was introduced into the 
anti-tuberculosis treatment, which could be reduced further to only six 
months (Palomino 2007).  
Two biological features explain why combined drug therapy is 
more effective at curing TB than mono-therapy. One is that treatment 
of active TB with a single drug results in the selection of drug 
resistant bacilli and failure to eliminate the disease. The other is that 
different populations of tubercle bacilli each of them showing a 
distinct pattern of susceptibility for anti-tuberculosis drugs may co-
exist in a TB patient (Shamputa, 2006). Soon after the introduction of 
the first anti-mycobacterial drugs, drug resistant bacilli started to 
emerge, but the launch of both combination therapy and new and 
more effective drugs seemed to be enough to control the disease. In 
fact, it was thought that TB could be eradicated by the end of 20th 
century. However, TB unexpectedly re-emerged in the ’80s, and in the 
following years there was an important increase in the incidence of 
poly-, multiple-, and extensively drug resistant strains (Palomino 
2007).  
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Since 1970, no new drug has been discovered for anti-
tuberculosis treatment, which today seems insufficient to confront the 
disease. Fortunately, research efforts have been accomplished and 
today there is a wide range of new molecules with promising anti-
tuberculosis activity. Now, due to the worldwide re-emergence of TB 
and the increased incidence of multidrug resistant MDR, (MDR-TB is 
define as Mycobacterium tuberculosis strains are  resistant to at least 
RIF and INH, the two key first line drugs in short course TB 
chemotherapy (Aziz et al 2006, Paluch et al 2008) and extensively 
drug resistant (XDR- MTB isolates that resistant to RIF and INH and 
at least to three of the six main classes of  second line drugs 
(aminoglycosides, polypeptides, fluoroquinolones, thioamides, 
cycloserine and para aminosalicylic acid) strains of Mycobacterium 
tuberculosis (WHO 2008, CDC 2006),  new anti-mycobacterial agents 
, new drug delivery systems (Gelperina et al 2005), and new treatment 
regimens are being investigated. 
Anti-tuberculosis treatment has two main objectives first; there 
is a need to rapidly kill those bacilli living extracellularly in lung 
cavities. Second, it is necessary to achieve complete sterilization and 
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elimination of those bacilli replicating less actively in acidic and 
anoxic closed lesions, and to kill semi-dormant bacilli living 
intracellularly in other host tissues, otherwise these bacilli may persist 
and will be responsible for subsequent TB relapses. INH is the drug 
with the highest activity against rapidly dividing bacilli, whereas RIF 
and PZA have the greatest sterilizing activity against bacteria that are 
not dividing. These reasons, along with the prevention of drug 
resistance, support the use of a combination therapy for the treatment 
of TB (Onyebujoh et al 2005). 
Drugs for treating TB are usually classified as first- and second-
line drugs. Traditionally, there are five first-line drugs: INH, RIF, 
PZA, EMB, and SM (table1-1). Second-line drugs include the 
aminoglycosides kanamycin and amikacin, the polypeptide 
capreomycin, PAS, cycloserine, the thioamides ethionamide and 
prothionamide and several fluoroquinolones such as moxifloxacin, 
levofloxacin and gatifloxacin tuberculosis treatment (WHO 2008a), 
(table 1-2).  The current short-course treatment for the complete 
elimination of active and dormant bacilli involves two phases: initial 
phase: three or more drugs (usually isoniazid, rifampicin, 
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Pyrazinamide and ethambutol or streptomycin) are used for two 
months, and allow a rapid killing of actively dividing bacteria, 
resulting in the negativization of sputum  and continuation phase: 
fewer drugs (usually isoniazid and rifampicin) are used for 4 to 7 
months, aimed to killing any remaining or dormant bacilli and 
preventing recurrence, the 2-month rifampicin regimen (2INH-RIF-
PAZ-EMB/6INH-EMB) is associated with more relapses and deaths 
than the 6-month rifampicin regimen (2INH-RIF-PZA-EMB /4INH-
RIF) (WHO 2008a, Menzies et al 2009).  
At the global level, 15% of previously treated patients have 
MDR (WHO 2008a), which is five times higher than the global 
average of 3% in new patients. Even in Africa, the WHO region 
thought to have the lowest level of MDR in retreatment patients, 
significant proportions (6%) of retreatment patients have MDR-TB 
(WHO 2008a). If their MDR is not detected and treated with second-
line drugs, these patients will suffer poor outcomes and spread MDR 
in their communities. 
The World Health Organization (WHO) has established four 
TB diagnostic categories, assuming from a public health perspective 
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that the highest priority of national TB programs is to identify and 
cure those patients with sputum smear-positive pulmonary TB, i.e. 
infectious TB patients (WHO 2003, CDC 2003).  
Category I: comprises those patients with a high priority for 
treatment who are new smear-positive patients, new smear-negative 
pulmonary TB patients with extensive parenchymal involvement, 
patients with concomitant HIV/acquired immunodeficiency syndrome 
(AIDS) disease or severe forms of extra pulmonary TB.  
 Patients with a lower priority for treatment are classified as follows:  
Category II: (relapse, treatment failure or default) 
Category III: (new smear-negative pulmonary TB other than in 
Category I and less severe forms of extra pulmonary TB). 
Category IV: (chronic sputum-positive TB after re-treatment and 
proven or suspected MDR-TB). Preferred and optional treatment 
regimens for each category, as recommended by the WHO (2003). 
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  Table 1.2 Recommended doses for second-line anti-tuberculosis drugs 
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Table 1.2 Recommended doses for second-line anti-tuberculosis drugs 
Drug Adults or 
Childrena 
Dose 
(Max. dose 
Dose per week
Rifapentineb Adults 10 mg/kg (600 
mg) One               
One 
Rifabutinc Adults 5 mg/kg (300 
mg)  
2/3 or seven 
Cycloserine Adults & Children 10-15 mg/kg (1 
g) 
Seven 
Ethionamide Adults & Children 15-20 mg/kg (1 g) Seven 
Amikacin Adults 15 mg/kg (1 g) 1/2/3 or seven 
Kanamycin Children 15-30 mg/kg (1 g) Two or seven 
PAS Adults 8-12 g Seven 
Children 200-300 mg/kg 
(10 g) 
Seven 
Levofloxacind Adults 500-1,000 mg Seven 
Moxifloxacind Adults 400 mg Seven 
Centers for Disease Control and Prevention, 2003a. 
a : Patients under 15 years of age. 
b : This drug has not been approved for use in children. 
c : Doses of rifabutin may need to be adjusted in HIV-positive pa  
tients receiving  antiretroviral  therapy. 
 d : This drug has not been approved for long-term use in children 
and   adolescents. 
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1.12. Drugs and drug resistance mechanisms 
1.12.1. Natural drug resistance 
The natural drug resistance of M. tuberculosis is an important 
obstacle for the treatment and control of TB. This resistance has 
traditionally been attributed to the unusual multi-layer cell envelope 
and active multidrug efflux pumps (De Rossi et al 2006, Jarlier and  
Nikaido 1994). Recent insights into mechanisms that neutralize the 
toxicity of antibiotics in the cytoplasm have revealed other systems 
that function in synergy with the permeability barrier and efflux 
systems to provide natural resistance. Drugs inhibiting these intrinsic 
systems would enable many antibiotics, which are already available 
but have not been used for TB, to gain a new potential use against M. 
tuberculosis (Lomovskaya and Bostian 2006, Nguyen and Thompson 
2006). 
1.12.2. Acquired drug resistance 
Acquired drug resistance is mediated by plasmids or 
transposons, but in contrast, M. tuberculosis acquire drug resistance 
by mutations in chromosomal genes (Heym et al 1994). So far, no 
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single pleiotropic mutation has been found in M. tuberculosis to cause 
a MDR phenotype.     
The MDR phenotype is caused by sequential accumulation of 
mutations in different genes involved in resistance to individual drugs, 
due to inappropriate treatment or poor adherence to treatment (Zhang 
and Telenti 2000). However, it is important to observe that some 
resistant strains do not present these classic mutations, suggesting the 
possibility of the existence of other mechanisms such as efflux pumps 
and alterations in the permeability of the cell wall. 
1.12.2.1 Isoniazid (INH) 
INH was synthesized in 1912 by the Czech chemists Hans 
Meyer and Josef Mally, but it was not until 1952 that it was 
introduced as an anti-tuberculosis agent. The first indication of the 
mechanism of action of INH was obtained from the observation that 
as soon as the treatment with INH began, the acid-fast property of the 
tubercle bacillus was quickly lost. In 1970, it was demonstrated that 
INH inhibits mycolic acids synthesis, which explained the 
microscopic observation of the loss of the acid-fastness (Blanchard 
1996). 
33 
 
INH has a simple structure, containing a pyridine ring and a 
hydrazide group and both molecules are essential for its high activity 
against M. tuberculosis. Despite its simple structure, the mode of 
action of INH is very complex (Bernstein et al 1952). An important 
aspect to underline is that INH is a prodrug; its antibiotic action 
depends on the bacterial activation by the catalase-peroxidase enzyme 
(KatG) (Zhang et al 1992) to generate reactive radicals, which attack 
multiple targets in M. tuberculosis (Zhang et al 2000). 
The main target of INH is the pathway synthesizing cell wall 
mycolic acids (Takayama et al 1972). Furthermore, at least two 
enzymes, InhA (enoyl acyl carrier protein reductase) (Banerjee et al 
1994) and KasA (beta-ketoacyl ACP synthase) (Mdluli et al 1998) 
have been identified as targets for INH. Resistance to INH is mostly 
associated with mutations or deletions in katG; other mutations related 
with INH resistance occur in the coding region of inhA gene (or its 
promoter) and kasA. Furthermore, mutations in several other genes 
have been reported to be associated with INH resistance, but occur 
less frequently, and their association with INH resistance is less clear 
(Sreevatsan et al 1997, Ramaswamy et al 2003). 
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1.12.2.2. Rifampicin (RIF) 
A lipophilic ansamycin was introduced in 1972 in the treatment 
of TB. Due to its efficient antimicrobial action, it is considered, 
together with INH, to be the basis of the short-course treatment 
regimen (Rattan et al 1998). RIF associates with the beta-subunit of 
the ribonucleic acid (RNA) polymerase, inhibiting the elongation of 
the messenger RNA (mRNA) (Blanchard 1996). RNA polymerase is 
an oligomer consisting of a catalytically competent core enzyme 
formed by four subunits (two alpha subunits, and beta and beta-prime 
subunits) in association with another subunit, sigma, which is able to 
specifically initiate transcription (Zhang  and Telenti 2000). 
Almost all clinical isolates of M. tuberculosis resistant to RIF 
show mutations in rpoB, the gene that encodes the beta-subunit of the 
RNA polymerase, resulting in conformational changes that determine 
the low affinity of this subunit for RIF and consequently, resistance to 
the drug (Jin and Gross 1988, Williams et al 1994). Mutations 
conferring resistance to RIF are clustered in three short regions in the 
central region of the beta-subunit gene: cluster I (amino acids 512 to 
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534), cluster II (amino acids 563 to 574) and cluster III (amino acid 
687) (Zhang and Telenti 2000). 
1.12.2.3. Pyrazinamide (PZA) 
Is structurally similar to nicotinamide, and is converted into the 
acid form (pyrazinoic acid) by the bacterial pyrazinamidase enzyme 
(PZase) (Konno et al 1967). PZA is active against bacilli in a semi-
dormant state. Its introduction into the primary treatment of TB 
allowed the reduction of the treatment from nine to six months. This 
property has been attributed to its ability to inhibit semi-dormant 
bacilli residing in acidic environments (Zhang and Telenti 2000). 
The antimicrobial action of PZA is highly specific for M. 
tuberculosis, with little or no activity against other mycobacteria, 
including M. bovis. The reason for the specific activity of PZA against 
M. tuberculosis is because this drug needs to be activated by the 
PZase enzyme, which is encoded by the pncA gene. This gene is 
altered in many species of mycobacteria, which are resistant to PZA 
because they lack an efficient PZase. In M. bovis, for example, the 
substitution of the His residue in position 57 for Asp produces a non-
effective PZAse (Konno et al 1967). In most cases, resistance to PZA 
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is associated with mutations in pncA. PZA resistant strains have 
shown a wide range of alterations in the 630 bp of the open reading 
frame or in the 82 bp of the promoter region (Scorpio and Zhang 
1996). Some PZA-resistant strains do not present any alterations in 
the coding region or the promoter of the pncA gene. For these strains, 
it has been postulated that PZA resistance could be due to mutations 
in an unknown pncA regulatory gene (Cheng et al 2000). 
1.12.2.4. Ethambutol (EMB) 
Is a synthetic compound used as first-line drug for anti-
tuberculosis therapy in combination with other drugs, as 
recommended by the WHO. It has been demonstrated that EMB acts 
on enzymes involved in the biosynthesis of arabinogalactan 
(Takayama and Kilburn1989), inhibiting the polymerization of cell 
wall arabinan of arabinogalactan and of lipoarabinomannan 
(Mikusova et al 1995). In M. tuberculosis, the emb operon has three 
contiguous genes: embC, embA, and embB, which encode 
mycobacterial arabinosyl transferases (Telenti et al 1997). These 
enzymes have been considered the drug targets for EMB, since 
substitutions of codon 306 in the M. tuberculosis embB gene have 
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been shown to be the most frequent and predictive mutations for EMB 
resistance (Srivastava et al 2006). For strains with the Met306Leu or 
Met306Val replacements, EMB MICs were generally higher (40 
mg/L) than those for organisms with Met306Ile substitutions (20 
mg/L). In M. tuberculosis, mutations in genes other than embB have 
been associated with EMB resistance. Often these mutations affect     
a putative regulatory sequence in the embC–embA intergenic region 
(Ramaswamy et al 2000). 
1.12.2.5. Streptomycin (STM) 
Is an aminocyclitol glycoside antibiotic that was the first 
antibiotic used for the treatment of TB. SM inhibits the initiation of 
mRNA translation affecting translation fidelity (Moazed and Noller 
1987). Mutations associated with SM resistance in M. tuberculosis 
have been identified in the 16S ribosomal RNA (rRNA) gene (rrs) 
and rpsL gene encoding ribosomal protein S12 (Finken et al 1993). 
The majority of point mutations producing SM resistance occur in 
rpsL and the most common mutation is an AAG->AGG change in 
codon 43, which results in a Lys->Arg substitution; less frequently, an 
AAG->ACG (Lys->Thr) substitution is observed (Bottger 1994, 
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Musser 1995). The second mechanism of SM resistance in M. 
tuberculosis is mutation in rrs.  
Mutations in rpsL and rrs have been identified in 50 and 20 % 
of SM resistant clinical isolates, respectively, resulting in high or 
intermediate levels of SM resistance respectively. There are some 
clinical isolates that show low level SM resistance in which no 
mutation in rpsL or rrs has been found (Zhang and Telenti 2000). It 
has been hypothesized that changes in the cytoplasm concentration of 
SM due to the action of efflux pumps could be the molecular basis of 
SM resistance in these strains (Aínsa et al 1998, Meier et al 1996, 
Silva et al 2001). 
1.12.2.6. Fluoroquinolones 
The main targets of the quinolones are the deoxyribonucleic 
acid (DNA) gyrase, a type-II DNA topoisomerase composed of two A 
and two B subunits encoded by genes gyrA and gyrB, respectively 
(Takiff et al 1994), and DNA topoisomerase IV (Drlica and Malik 
2003). High-level resistance to fluoroquinolones in laboratory strains 
of M. tuberculosis and M. smegmatis (Takiff et al 1994) is known to 
result from amino acid substitutions in the putative fluoroquinolone 
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binding region of the M. tuberculosis gyrA or gyrB genes (Aubry et al 
2004, Cambau et al 1994). This is the only type II topoisomerase 
encoded in the M. tuberculosis genome (Cole 1998b) and thus, is the 
unique target for fluoroquinolones in this organism (Aubry et al 
2004). 
1.12.2.7. Cycloserine 
Inhibits the biosynthesis of the mycolylarabinogalactan-
peptidoglycan complex by interfering with the activity of D-alanine 
racemase or D-alanine ligase enzymes. Resistance results from the 
overexpression of the AlrA enzyme – due to a single transversion (G 
Õ T) at the alrA promoter in cycloserine resistant strains (Chopra and 
Brennan 1998). 
1.13. Gene mutation studies 
Mycobacterium tuberculosis is a slow growing microorganism. 
Therefore, an antimicrobial susceptibility test based on traditional 
methods may be time consuming (Marttila et al 1996). The need to 
minimize the transmission of drug-resistant TB strains resulted in the 
development of DNA amplification assays that greatly shorten 
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antimicrobial resistance detection time. These assays are used as rapid 
additional tools assisting TB control programmes in the screening of 
resistant strains from clinical samples (Felmlee et al 1995). The 
genetics of antimicrobial resistance have been elucidated in part for 
M. tuberculosis, enabling certain genes to be associated with 
resistance to anti-TB drugs: katG, inhA, aphC, kasA for isoniazid 
resistance; rpoB for rifampin resistance; rpsL and rrs for streptomycin 
resistance; embB for Ethambutol resistance; pncA for Pyrazinamide 
resistance; and gyrA for fluoroquinolones. Resistance to multiple 
drugs is the consequence of an accumulation of mutations. PCR-
RFLP, PCR-SSCP, PCR-CFLP, PCR-ddF, PCR-LiPA, PCR-
molecular beacon sequence analysis, PCR-HDP analysis, PCR-dot 
blot, rifoligotyping (rifampicin oligonucleotide typing) and PCR-
DNA sequencing have all been employed to detect mutations 
associated with specific drug resistance (Brow et al 1996, Felmlee et 
al 1995, Marttila et al 1996, Rossau et al 1997). 
1.13.1 rpoB gene 
rpoB is a highly conservative gene that has a basic role in the 
physiology of the bacteria. It encodes the B- subunit of RNA 
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polymerase (Lee et al 2000). It can be used in species identification of 
mycobacteria and epidemiologic tool for rifampicin resistant 
mycobacterium tuberculosis isolates. DNA sequencing studies 
indicate that more than 96% of RIF resistant MTB have mutation 
within 81-bp hot spot region of rpoB gene, which is known as 
rifampicin resistant determining region(RRDR)(Bobadilla et al 2001). 
1.14. Diagnostic approaches 
1.14.1. Systemic symptoms and signs of pulmonary tuberculosis 
Although systemic signs and symptoms are classically ascribed 
to TB, and are indeed very important for diagnostic suspicion, it 
should be kept in mind that they are nonspecific and can be present in 
other diseases of insidious evolution, particularly other bacterial and 
mycotic bronchopulmonary infections, lung cancer, and chronic 
diseases with lung involvement (Wise and Marella 2003). However 
the most common symptoms and signs of tuberculosis are; fever and 
sweating, weight loss and respiratory symptoms and signs of 
pulmonary tuberculosis  are; dry cough but with progression, it 
becomes productive with mucous or mucopurulent expectoration, 
hemoptysis, dyspnea, thoracic pain and hoarseness This occurs when 
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the larynx is affected, which is frequent with pulmonary TB. It rarely 
occurs in other forms of the disease. When cough and other symptoms 
are overlooked by the patient, hoarseness may be the sole reason for 
seeking medical assistance. (Smith and Weinstein 1994, Simon et al 
1977, Wise and Marella 2003). 
1.14.2. Physical examination 
Physical signs in TB are related to the extent of the lesions, the 
duration of the disease and the form of presentation. The longer the 
duration of the disease, the more evident are the classic signs of 
consumption, such as pallor and weight loss (Peroncini 1979). The 
extent and the form of the disease in the lung parenchyma determine 
the presence of specific pulmonary signs. The most common 
auscultation findings are: coarse crackles in the area corresponding to 
the lesion (generally apical and posterior); wheezing and ronchi in the 
area of compromised bronchi; clinical signs of lung condensation in 
the forms with caseous pneumonia; decreased vesicular murmur and 
broncophony or tubular blow when pleural effusion is present; as well 
as the classic amphoric breath sounds near cavities. Hepatosplenom-
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egaly can occur in the disseminated forms (Azambuja et al 1993, 
Kasik 1994, Norris  and BucKley 1995). 
Some findings are caused by delayed-type hypersensitivity to 
tubercle bacilli components, although the lesions themselves do not 
contain M. tuberculosis. These TB associated conditions are: 
erythema nodosum (inflammation of the subcutaneous adipose tissue), 
phlyctenular conjunctivitis, erythema induratum of Bazin (nodular 
vasculitis) and polyserositis. These lesions are mostly associated with 
primary TB infection, although they may also be observed in re-
activation TB disease and sometimes are recurrent (Norris and 
BucKley 1995) 
1.14.3. Radiological Method 
Chest X- rays are traditional diagnostic tools for tuberculosis. 
They provide immediate results without waiting for several weeks as 
in culture. There are numerous disadvantages to rely on X-rays for 
diagnosis, firstly the technique has very poor specificity with many 
others chest conditions resulting in similar radiographic abnormalities 
and this will lead to over-diagnosis and unnecessary prescription of 
antibiotic against tuberculosis. Sensitivity is also poor with the early 
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stages of infection failing to appear in X- ray (Kline et al 1995). 
Finally X- ray cannot be used to determine whether the patient is part 
of an outbreak, or simply suffering reactivation of an old infection. 
For these reasons X-rays should only be used as a diagnostic tool in 
conjunction with smear and cultures. 
1.14.4 Laboratory diagnosis of tuberculosis  
1.14.4.1 Conventional diagnostic methods 
Active tuberculosis is diagnosed by detecting Mycobacterium 
tuberculosis complex bacilli in specimens from the respiratory tract 
(pulmonary TB) or in specimens from other bodily sites (extra-
pulmonary TB). Although many new (molecular) diagnostic methods 
have been developed, acid fast bacilli (AFB) smear microscopy and 
culture on Löwenstein-Jensen medium are still the “gold standards” 
for the diagnosis of active TB and, especially in low-resource 
countries, the only methods available for confirming TB in patients 
with a clinical presumption of active disease. AFB smear microscopy 
is rapid and inexpensive and thus is a very useful method to identify 
highly contagious patients (Kent and Kubica 1985). Culture is used to 
detect cases with low mycobacterial loads and is also requested in 
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cases at risk of drug-resistant TB for drug susceptibility testing, or in 
cases where disease due to another member of the Mycobacterium 
genus is suspected. AFB smear microscopy and culture can also be 
used to monitor the effectiveness of treatment and can help to 
determine when a patient is less likely to be infectious ((Kent and 
Kubica 1985). 
Accurate case detection is the rate-limiting step in TB control 
(Perkins and Kritski 2002). While as many as two thirds of sputum 
smear-positive cases probably remain undetected worldwide, the 
efforts to control the disease have focused more on curing TB cases 
than on detecting them. (Gupta et al 2004, Dye et al 2003). Even 
though the laboratory is essential for the diagnosis and control of TB, 
it does not receive enough attention in developing countries, where 
AFB sputum microscopy is often the only available method to 
diagnose TB. Sputum microscopy lacks sensitivity, especially in 
children and in people living with human immunodeficiency 
virus/acquired immunodeficiency syndrome (HIV/AIDS). Its 
usefulness depends largely on the quality of the sputum specimen and 
the performance quality of the laboratory. Considerable efforts have 
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been made to improve the sensitivity of sputum smear microscopy 
(Steingart et al 2006). 
1.14.4.1.1 Immunological diagnosis 
Immuno-diagnosis is considered for rapid and cost-effective 
diagnostic methods. Basically, it uses the specific humoral and 
cellular immune responses of the host to infer the presence of 
infection or disease. Different serological tests are used for detection 
of antibodies in individuals suspected to have TB and also to detect 
the active disease (Gennaro 2000, Chan et al 2000). These tests are 
good in patients that are unable to produce adequate sputum, in 
negative smear patients and extra-pulmonary TB patients. The 
tuberculin skin test (TST) and, interferon gamma (IFN-γ) production 
are examples of serological tests (Huebner et al 1993, Prabhakar et al 
2004).  
 1.14.4.1.1.1 Tuberculin skin test 
Tuberculin skin test (TST) has been used to identify patients 
actively infected with TB, to measure the prevalence of infection in a 
community, and to select susceptible or high-risk patients for BCG 
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vaccination. The test has been in existence for more than 100 years 
and has remained more or less unchanged for the last 60 years 
(Huebner et al 1993, Curley 2003). 
TST works by intradermally injecting 0.1 mL of 5 TU PPD on 
the forearm. On examination, after 48-72 hours, a positive reaction is 
indicated by erythema and induration of > 10 mm in size. Erythema 
(redness) alone is not taken as a positive reaction. All persons with 
prior infection with tubercle bacilli will mount an immune response to 
bacilli proteins (Curley 2003). 
1.14.4.1.2 Microscopy 
AFB smear microscopy plays an important role in the early 
diagnosis of mycobacterial infections because most mycobacteria 
grow slowly and culture results become available only after weeks of 
incubation. In addition, AFB smear microscopy is often the only 
available diagnostic method in developing countries. Smear staining is 
based on the high lipid content of the cell wall of mycobacteria which 
makes them resistant to decolonization by acid-alcohol after the 
primary staining. To determine that a clinical specimen contains AFB, 
the specimen is spread onto a microscope slide, heat-fixed, stained 
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with a primary staining, decolorized with acid-alcohol solution and 
counterstained with a contrasting dye in order to obtain better 
differentiation between the microorganism and the background (WHO 
1998a). The slide is observed under the microscope for the detection 
of AFB. Several methods can be used for determining the acid-fast 
nature of an organism. Two methods; Ziehl-Neelsen and Kinyoun, 
utilize basic fuchsin in ethanol for primary staining (Kleeberg et al 
1980). In both cases, AFB appears red after decolonization with acid 
alcohol. Ziehl-Neelsen is a hot acid-fast stain because the slide has to 
be heated during incubation with fuchsin. In contrast, Kinyoun 
staining is a cold acid fast staining procedure and therefore does not 
require heating. Kinyoun's cold carbol fuchsin method is inferior to 
the Ziehl's-Neelsen staining (Somoskovi et al 2001, Van Deun et al 
2005).  
In the fluorochrome procedure, primary staining is done with 
auramine O. The AFB fluoresce yellow against a counter stain of 
potassium permanganate when observed with a fluorescence 
microscope. While the reading of fuchsin-stained smears requires 
100x magnification, fluorochrome-stained smears are examined at 25x 
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or 45x. The lower magnification used in this staining method allows 
the microscopist to observe a much larger area of the smear during the 
same period of time and thus, fewer fields must be read. This makes 
the method faster and reduces laboratorist fatigue. Allegedly, 
fluorescent staining is more sensitive than Ziehl's- Neelsen staining 
(Steingart et al 2006). However, it has been claimed that methods 
have comparable sensitivity, provided procedural standards are 
followed, and a minimum of 300 fields are read with the Ziehl's-
Neelsen staining (Somoskovi et al  2001). Because of the rapidity of 
the fluorochrome method, laboratories processing large numbers of 
specimens should adopt this technique. A real disadvantage of the 
fluorochrome method is that fluorescence fades with time. For this 
reason, the slides must be read within 24 hours. This staining method 
is not often available in developing countries due to the high cost of 
the fluorescence microscope and, especially, that of its maintenance. 
The results of the smear microscopy should be reported according to 
an internationally agreed quantitation scale. (Somoskovi  et al  2001).  
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1.14.4.1.3 Culture  
Acid-fast microscopy is easy and quick, but it does not confirm 
TB diagnosis because mycobacteria other than M. tuberculosis are 
also AFB in the smear microscopic examination (WHO 1998). In 
addition, a high bacterial load is needed in the specimen to ender an 
AFB microscopy result positive. Culture techniques have been 
estimated to detect as many as 10–1,000 viable mycobacteria per mL 
of specimen. All specimens should be submitted to culture, regardless 
of AFB smear microscopy results (WHO 1998). A positive culture for 
M. tuberculosis confirms the diagnosis of active disease, for culturing 
of mycobacteria, two types of clinical specimens are considered: 
contaminated specimens and specimens collected aseptically from 
normally sterile sites. Sterile specimens can be inoculated directly 
onto the culture medium. Specimens from non-sterile bodily sites are 
considered contaminated and therefore require processing before 
culturing in order to eliminate the associated flora. If not properly 
eliminated, this flora will overgrow the culture medium long before 
mycobacteria have the chance to develop visible colonies (WHO 
1998, Blumberg 1995). 
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1.14.4.2. Use of nucleic acid amplification for TB diagnosis 
In industrialized countries, the advent of rapid nucleic acid 
amplification (NAA) tests for tuberculosis is seen as a major 
breakthrough in the management of PTB (Brodie and Schluger  2005). 
Several commercial NAA tests have undergone validation and are 
licensed for routine testing of sputum. They have specificities of > 95 
% for smear positive specimens, but sensitivities are variable, 
especially in smear-negative disease, where a rapid diagnostic test is 
most needed. In house NAA tests have been proposed for developing 
countries due to their low cost. In a recent meta-analysis of in house 
NAA tests for the detection of M. tuberculosis in sputum specimens, 
the use of IS6110 as the target appeared to be associated significantly 
with higher diagnostic accuracy (Flores et al 2005). The majority of 
studies on the use of NAA for TB diagnosis have been performed in 
industrialized countries, where there is low burden of TB/HIV and 
history of pulmonary TB, and where false positive NAA results may 
occur due to M. tuberculosis DNA detection in the absence of active 
TB (Sloutsky et al 2004). Few series have estimated the potential 
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clinical utility of these tests in relation to different levels of clinical 
suspicion and pretest probability (Cantazaro et  al 2000). 
For developing countries, where almost 100 % of smear-
positive results represent TB disease, it has been emphasized that 
NAA tests increase sensitivity among smear-negative pulmonary TB 
cases. In these settings, the published evaluations of NAA techniques 
for smear-negative TB diagnosis have mainly been based on 
laboratory criteria for the diagnosis of disease (Kivihya et al  2004), 
with or without the use of clinical records to evaluate discrepant 
results (Laifer et al  2004). In addition, it has been emphasized that 
many laboratories in those countries did not use adequate quality 
controls to evaluate the performance of PCR (Suffys et al  2000). 
Automated NAA or in house PCR might be more widely introduced 
in developing nations only after a proper evaluation of cost-
effectiveness, together with analysis of clinical and radiographic 
characteristics, to refine estimates of the likelihood of TB disease in 
those settings, as proposed by others (Van Cleef et al 2005). 
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1.15 Identification of M. tuberculosis 
1.15.1 Biochemical procedures 
The final species identification of M. tuberculosis is based on 
characteristics such as slow growth, colony morphology, and 
biochemical tests. From a practical point of view, most isolates from 
human disease belong to the species M. tuberculosis (Tsukamura 
1984). However, depending on geographical and epidemiological 
circumstances, it may be necessary to differentiate species within the 
M. tuberculosis complex. An initial identification as M. tuberculosis is 
defined on AFB bacilli from slow growing, non-pigmented colonies 
that are niacin positive, are inhibited by p-nitro benzoic acid and 
display nitrates activity. Additional tests that confirm an isolate as M. 
tuberculosis are susceptibility to Pyrazinamide, growth on hyphened 
carboxylic acid hydrazine, absence of catalase production at 68°C and 
absence of iron uptake, (WHO 1998, Vincent et al 2003, Tsukamura 
1984). (table 1-3) summarize the differential characteristics of species 
in the MTBC.  
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Table 1.3 Colony morphological and biochemical characteristics 
of species in the M. tuberculosis complex 
Test M. 
tuberculosis
M. 
bovis 
M. bovis
BCG 
M. 
africanum
M. 
microti 
M. 
canettii
Morphology   rough rough rough rough rough smooth 
 Pyruvate rather 
than  glycerol as 
carbon source 
- + + - - - 
Pyrazimidase + - - + + + 
Niacin + - - +/- + - 
Nitratase + - - +/- - + 
Urease  +/- - - +/- +/- - 
Susceptibility 
to TCH  
R S S S S R 
O2 
requirement 
aerobic 
 
aerobic 
Microae
rophilic
aerobic Microaer
ophilic 
 
Microa
erophili
c 
 
unknown
R= resistant, S= susceptible, TCH= Thiophene-2-carboxylic acid 
hydrazide 
1.15.2 Molecular technique 
In the last two decade, advances in molecular methods have 
facilitated the rapid and reliable identification of many mycobacterial 
55 
 
species by molecular means. Nucleic acid probes, species-specific 
PCR, reverse hybridization and 16S rRNA sequencing have been 
evaluated for application in clinical laboratories (Goto et al 1991, 
Lebrun et al 1992,  Patel et al  2000,  Hall et al 2003, Sarkola et al 
2004). Due to its ease of use and commercial availability, (AccuProbe, 
GenProbe Inc.) is now incorporated into the workflow of many 
mycobacterial laboratories (Goto et al 1991, Lebrun et al 1992).  
1.15.2.1 Molecular Identification of species within the MTBC 
The high degree of sequence conservation among members of the M. 
tuberculosis complex makes differentiation of species in the clinical 
mycobacteriology laboratory a difficult task. Routine differentiation is 
still based on phenotypic characteristics, such as oxygen preference, 
niacin accumulation, nitrate reductase activity, colony morphology, 
and resistance to two compounds, TCH and PZA. M. tuberculosis is 
the most frequent cause of human TB, but some cases are caused by 
M. bovis. It is necessary to differentiate between M. bovis and M. 
tuberculosis in order to know the prevalence and distribution of 
human TB due to M. bovis. This may contribute to knowledge about 
the risk factors associated with the transmission  of M. bovis to the 
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human population M. bovis differs from M. tuberculosis in having a 
low growth rate on egg media supplemented with glycerol, but a faster 
growth on egg media supplemented with pyruvate (Stonebrink 
medium). M. bovis isolates are resistant to PZA, while M. tuberculosis 
strains are generally considered PZA-sensitive (Palomino et al 2007). 
Several molecular techniques were designed to differentiate M. 
tuberculosis complex, including methods to detect mutations in pncA 
and oxyR genes (Scorpio and Zhang 1996), mtp40-PCR (Del Portillo 
et al 1991,  Liebana et al 1996), and PCR-amplification of regions of 
difference (RD) (Parsons et al 2002,  Huard et al 2003), A species 
specific mycobacterial DNA element in the M. tuberculosis complex 
(Del Portillo 1991), the M. tuberculosis mpt40 fragment (Viana et al 
2004), Spoligotyping (Kamerbeek et al 1997, Zumarraga et al 1999b) 
and RD (Brosch et al 2002).  
1.16 Molecular epidemiology of tuberculosis 
1.16.1 Genotyping 
Different strains of M. tuberculosis form a very homogenous 
group at the phenotypic level. Classification of the disease evolved 
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from differentiation of new cases of reactivated tuberculosis and 
acquired versus primary of drug resistant tuberculosis cases. Typing 
schemes that exploited phenotypic characteristics e.g. antigenic 
factors, resistance to defined antibiotics, susceptibility to phage 
infection and the production of certain chemical substances brought 
with them a glimpse of hope. The major drawback of these traditional 
methods was that markers used were often species-specific and 
relatively weak in identifying/confirming specific strains (Saunders 
1999, Van Soolingen et al 2001). Strain typing is, however, a 
powerful TB control tool that became more practical with the 
introduction of procedures based on DNA analysis. DNA typing 
differentiates organisms (even of the same species) on the bases of 
genetic variation at the level of chromosome or gene. This approach 
was made possible by the discovery of the DNA insertion element, 
IS6110, 1355 bp long, present in different copy numbers (0-25 copies) 
and locations throughout the genome of M. tuberculosis, although this 
insertion element can transpose to induce genetic recombination, 
rearrangements and insertion/deletion mutations, the frequency of 
change is relatively slow giving this method great molecular 
epidemiological power. A standard restriction fragment length 
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polymophism (RFLP) method using the IS6110 as a hybridisation 
target has been agreed upon internationally to enable comparison of 
results (Saunders 1999, Van Soolingen et al 2001). The 
discriminatory potential of this method is a function of the number 
IS6110 copies present (Palomino et al 2007). 
 The higher the IS6110 copy number, the greater the likelihood 
that two or more identical RFLP patterns correspond to 
epidemiologically related strains. However, patterns containing few 
IS6110 copies, even if identical, may correspond to epidemiologically 
unrelated cases of the disease (McHugh et al 1998). Thus, other 
genetic markers must be used for confirming relatedness between 
strains exhibiting identical RFLP patterns. More than 16 different 
insertion sequences (IS) belonging to five IS families have been 
documented in the TB bacillus (e.g. IS1081, IS1547 etc). However, 
little polymorphism is observed when using these sequences as 
epidemiological markers. Many other DNA fingerprinting techniques 
have since been discovered and are used in cases where the IS6110 
based method is found to be insufficient (Kamerbeek et al 1997). The 
most commonly used alternatives include the polymorphic GC-rich 
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tandem repeat sequence (PGRS), a repeat of the triplet GTG, the 
direct repeat sequence typing (Spoligotyping), and the mycobacterial 
interspersed repeat units (MIRU) method. For spoligotyping each of 
the 43 spacer sequences found in the direct repeat domain of the 
genomic DNA is detected by a specific probe. The presence or 
absence spacer or sequences is used in the differentiation of strains. 
MIRUs are repeat sequences found in tandem and are of variable 
numbers in intergenic regions (Saunders 1999). 
Estimation of the length in base pairs of each provides an 
indication of the number of repeats in that locus. The 12 most 
polymorphic MIRU-VNTR give a 12-number configuration that can 
be used to differentiate strains (Saunders 1999, Kamerbeek et al 1997, 
Supply et al 1997). 
Initially, the IS6110-directed RFLPs were used to confirm 
suspected cases of transmission, to detect laboratory contamination 
and to study disease outbreaks. Most studies have focused on tracing 
tuberculosis among contacts, for example, outbreaks among HIV -
positive instutionalised people, bar patrons and churchgoers. Presently 
this tool is used to characterize the clones that are circulating in a 
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particular restricted geographic region. Analyses of DNA fingerprints 
have also shed light on the routes of transmission and the degree of 
recent transmission versus reactivation (Warren et al 1996). This 
method is used worldwide to monitor transmission of TB strains, even 
across geographical borders (Mazurek et al1991, Casper et al 1996). 
Studies on the molecular epidemiology of tuberculosis have almost 
invariably shown the global dissemination strains belonging to the 
Asian lineage, designated W-Beijing clonal family of strains. This 
family of strains is associated with drug resistance in Asian countries. 
Subsequent investigations in Europe, United States of America, South 
Africa (Western Cape and KwaZulu-Natal), and other parts of the 
world discovered strains that are genetically related to the Beijing 
strain (Bifani et al 2002). 
1.16.2 The Random Amplified Polymorphic DNA (RAPD) assay  
RAPD assays are based on the use of short random sequence 
primers, 9 to 10 bases in length, which hybridize with sufficient 
affinity to chromosomal DNA sequences at low annealing 
temperatures such that they can be used to initiate amplification of 
regions of the bacterial genome. If two RAPD primers anneal within a 
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few kilo-bases of each other in the proper orientation, a PCR product 
with a molecular length corresponding to the distance between the two 
primers results. The number and location of these random primer sites 
vary for different strains of a bacterial species. Thus, following 
separation of the amplification products by agarose gel 
electrophoresis, a pattern of bands which, in theory, is characteristic 
of the particular bacterial strain results (Caetano et al 1991, Williams 
et al 1990). In most cases the sequences of the RAPD primers which 
generate the best DNA pattern for differentiation must be determined 
empirically. More recently, a consensus M13 DNA sequencing primer 
has been used in RAPD fingerprinting assays, which allows for some 
standardization of the procedure (Vila et al 1996, Webster et al 1996). 
1.16.3 Restriction fragment length polymorphism (RFLP) 
Differentiation of strains of M. tuberculosis complex using 
nucleic acid-based technology is based on strain specific differences 
and frequencies of certain DNA sequences in chromosomal DNA. 
This is usually demonstrated by digestion of the genomic DNA with 
specific restriction enzymes and analysis of the generated patterns 
after separation of the DNA fragments on agarose gel: restriction 
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fragment length polymorphism (RFLP) (Collins and Lisle 1984). This 
kind of analysis is technically possible and no hybridization step with 
defined probes is needed. However, interpretation of the results is 
difficult because the large number of fragments generates a complex 
pattern and only a small number of different RFLP types are observed 
(Palomino et al 2007). 
 1.16.4 Pulsed field gel electrophoresis (PFGE) 
Has been designed to simplify RFLP. The method uses a less 
frequently cutting enzyme that generates high molecular weight 
fragments and allows separation of these fragments under special 
conditions in PFGE. The main limitation of the technique is that the 
small polymorphism characteristic for different strains will not always 
produce sufficient discrimination (Varnerot et al 1992, Zhang et al 
1992a). 
1.16.5 RFLP with hybridization 
DNA polymorphism can also be demonstrated through 
hybridization of digested nucleic acids with genomic DNA or cloned 
fragments. Total DNA can be used as the probe but the use of the 
63 
 
complete genome as a probe usually results in considerable 
background and affects the interpretation of the results. Some study 
groups have used cloned repetitive DNA from M. tuberculosis as 
probes (Eisenach et al 1986 and 1988) and one of them appeared to 
differentiate all strains of M. tuberculosis analyzed (Zainuddin and 
Dale 1989). 
1.16.6 Methods based on repetitive elements. 
  Repetitive elements and insertion sequences are frequently used 
as target sequences for differentiation between mycobacterial strains. 
Five repetitive DNA elements(IS6110, IS1081, Polymorphic GC-rich 
repetitive sequence, element the major polymorphic tandem repeat 
(MPTR) and hotspot of integration of IS6110 contains a variable 
number of DR of 36 bp separated by unique spacer sequences of 35–
41 bp. ) are useful in strain differentiation of M. tuberculosis complex 
(Dale 1995, Poulet and Cole 1995). For use of repetitive sequences in 
epidemiological studies, polymorphism in different strains must be 
present.  
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1.16.7 Amplification-based methods 
The RLFP typing requires a well-grown culture for DNA 
extraction. The time lag between isolation of M. tuberculosis and 
growth of mycobacterial culture is often too long to inform patient 
care or outbreak investigation. More rapid typing techniques have 
been developed and most of them depend on PCR-based amplification 
of M. tuberculosis sequences including IS6110. PCR-based methods 
have the advantage of typing M. tuberculosis directly in clinical 
samples increasing the speed of identification of the organism. They 
can be used for non-viable isolates or when isolates cannot be 
resuscitated from archives. Some of these methods, however, lack 
reproducibility or have less discriminatory power than IS6110-RFLP 
(Kremer et al 1999). 
The most common types of the amplification-based methods 
are; 1- IS6110-based methods one of the methods is ampli-typing 
which is based on the use of oligonucleotide primers hybridizing with 
ends of IS6110 and generating a PCR reaction directed away from the 
insertion sequence (Yuen et al 1995). 2- 16S- and 23S rRNA-based 
methods Amplification of the spacer region between the genes coding 
65 
 
for 16S and 23S rRNA and digestion of the amplicon with restriction 
enzymes has also been performed for differentiation of M. 
tuberculosis strains (Abed et al 1995 and 1995a), and 3- DR region-
based methods A method based on detection of DNA polymorphism 
in the DR cluster (direct variable repeat PCR) has been used (Groenen 
et al 1993). 4- Spoligotyping is based on amplification of the DR 
region and subsequent differential hybridization of the amplified 
products with membrane bound oligonucleotides complementary to 
the variable spacer regions localized between the DRs. Strains that are 
similar or different can be distinguished by their spoligotype patterns, 
characterized by the number and identity of spacers (Van Soolingen et 
al 1995).5- Minisatellite-based methods; contain variable numbers of 
tandem repeats (VNTRs) have been demonstrated to be effective and 
portable methods for typing M. tuberculosis. (Supply et al 2000 & 
2001, Lee et al 2002) 
1.16.8. Application of typing methodology 
The availability of molecular typing techniques has enabled the 
epidemiology of tuberculosis to be studied effectively for the first 
time. There are several broad categories of question that may be 
66 
 
addressed by molecular typing methods: study of global, national or 
local transmission patterns, investigation of local outbreak, and 
detection of laboratory cross-contamination. Each of these requires a 
different combination of techniques. The best examples for this type 
are; 1- Large-scale national and international studies IS6110 are 
established as the international standard method for studying 
tuberculosis epidemiology. 2- Local outbreak investigation The RFLP 
has been used intensively for epidemiological purposes to trace 
outbreaks of disease (Van Soolingen et al 1991). It is very valuable in 
situations where traditional contact tracing would not be able to 
identify the source of infection. Genotyping has facilitated 
identification and characterization of strains associated with 
nosocomial transmission in hospitals (Valway et al 1994, Bifani et al 
1996, Frieden et al 1996, Moss et al 1997).  
1.17 Genetic sequencing 
Every genetic region which is highly conserved and, at the 
same time, includes moderately variable sequences is a potential 
target for identification (McNabb et al 2004, Ringuet et al 1999).. A 
number of such regions are known in the genome of living organisms; 
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among them, the best known include several genes: 16S ribosomal 
DNA, 23S ribosomal DNA, hsp65, and the non-encoding stretch ITS. 
The 16S ribosomal DNA, which is about 1,500 bp long, is by far the 
most popular target for sequencing, and the one for which the largest 
database is available. In this gene, universal sequences shared by 
practically every living organism co-exist with genus-specific 
sequences common to the organisms belonging to the same genus 
(e.g. the genus Mycobacterium) and with species-specific sequences 
that differentiate between species. With regard to the mycobacteria, 
almost all the sequences characterized by species-specific variability 
are concentrated in the first third of the gene, namely in two stretches 
called hypervariable region A and hypervariable region B. The first 
covers nucleotides between positions 130 and 210, and the second 
includes nucleotides from position 430 to position 500 (such numbers 
indicate the corresponding positions within the Escherichia coli 16S 
ribosomal RNA gene) (Rogall 1990a & 1990b). A practical 
consequence is that the determination of the nucleotide sequence of 
the first 500 bp of the gene allows the differentiation of almost all 
mycobacterial species known at present. 
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Genetic sequencing is nowadays performed using automatic 
sequencers that render it highly reproducible. Initially, the target 
region is PCR-amplified using proper primers and standard 
nucleotides. Then, the amplification product, once denatured, 
undergoes a second amplification in which the 3’ and the 5’ primers 
are used in separate tubes. In this step, in addition to standard 
nucleotides, a lower proportion of special nucleotides terminating the 
chain elongation are present. The random incorporation of terminator 
nucleotides during the amplification procedure (the four bases are 
marked with a different fluorochrome) produces strands whose 
lengths range from that of the primer elongated by a single nucleotide 
to that of the whole target ((Blackwood et al 2000). The amplicons, 
each marked with the fluorochrome specific for the nucleotide with 
which it ends, are put in order of length by means of electrophoresis. 
The emerging patterns of fluorescent markers identify the last bases of 
a continuous series of stretches, each being one nucleotide longer than 
the previous one, and consequently determine the genetic sequence of 
the region. It is very important to perform the sequencing of both 3’ 
(forward) and 5’ (reverse) strands, to carefully resolve the 
discrepancies (Palomino et al 2007) 
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Chapter Two  
Material and Methods  
 
2.1 Study design  
Cross sectional study was conducted during the period June 
2008 to June 2010. 
2.2 Samples size: 
Four hundred and twenty sputum samples were collected from 
420 patients diagnosed with pulmonary tuberculosis (AFB positive). 
2.3 Ethical considerations 
Ethical clearance was obtaind from the research ethics 
committee of Institute of Endemic Diseases and a signed informed 
written consent (appendix 3) was obtaind from patient prior to 
enrolment of the patients in the study.  
2.4 Defining of the study area 
Sputum specimens were collected from patients diagnosed with 
pulmonary tuberculosis (AFB positive) from DOT centers at; 
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Khartoum, Khartoum north Omdurman Wad Madani, Kassala, 
Gudarif, Damazeen and southern, northern and western parts of 
Sudan. Sudan map showing sites of collection. (Fig.  2.1).  
2.5 Inclusion criteria 
The specimens were collected only from patients already 
diagnosed with pulmonary tuberculosis (AFB positive), patients from 
different age groups (15- 70 years) who attended DOT (in & out 
patient) centers at the mentioned areas, after a detailed explanation 
concerning the ethics of the study was provided to each participant, 
and only the patients who well understood the consent form and 
accepted to sign or stamp it, were included. 
2.6 Exclusion criteria 
All patients under 15 years old, negative growth or 
mycobacterium other than tuberculosis complex, all patiens who 
refused to sign (or stamp) the consent form were excluded from the 
study. 
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2.7 The clinical specimens 
2.7.1 Patients 
The study population included 420 known cases of pulmonary 
TB patients (AFB  positive) from different age groups (15 to 70 
years), suffering from cough, fever and different other symbtims, 
belongs to different Sudanes tribes, who attended (in & out patient) 
DOT centers of the mentioned areas. The study group was categorized 
as new, re-treated patients with TB relapsed, treatment failure and 
defaulter. Samples were collected following approval of the institute 
all ethic committee and written consents were obtained for the 
participants, and data were collected using questionnaires. 
2.7.2 Data collection 
A detailed explanation concerning the ethics of the study was 
provided to each participant. Patients were enrolled only after giving a 
written consent form. Consented TB patient was fully interviewed to 
identify the risk factors related to the infection based on questionnaire 
(appendix 2). 
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2.8 Collection and processing of samples 
2.8.1 Sputum collection and processing 
Sputum samples were collected from all sputum smear positive TB 
patients who attending DOT centers in the defined areas. To collect 
the sample the patient was instructed to rinse his/her mouth with 
water, stand facing a wall, away from the wind and to cough deeply to 
produce the sputum. Sputum specimen from the productive cough was 
obtained in sterile screw-top plastic disposable wide mouth 
containers. (WHO 1998a, Yassin and Cuevas 2003).  
2.8.2. Isolation and Identification of mycobactera  
2.8.2.1. Ziehl’s- Neelsen (ZN) staining 
Ziehl’s- Neelsen stain was performed on the decontaminated 
sputum specimens which were collected according to WHO (1998a). 
The surface of the dried fixed slide which was placed on the staining 
rack was covered with carbol fuchsin (appendix 4), and then the 
slide was heated by spirit until rising of the vapor. After 5 min the 
slide was washed and covered with acid alcohol which remained on 
slide for 3 min and washed. Methylene blue (appendix 4) was added 
73 
 
onto the slide for one min, and rinsed (Gowan and Steel 1995). The 
slides were examined under the 100x oil immersion objective of a 
microscope for the detection of red or pink color against the blue 
counter stain background as acid fast bacilli that is vary in shape 
from short, coccoid to elongated filaments – single or in clumps and 
typically appear as long, slender curved rods and the result was 
reported according to International Union Against Tuberculosis and 
Lung Diseases (table 2-1). 
2.8.2.2. Isolation of mycobacteria 
The specimens were firstly decontaminated either by 4% NaOH or 
2%NaCl. The decontaminated specimens were inoculated onto 
Löwenstein-Jensen (LJ) medium containing pyruvate and glycerol, all 
procedures were performed under bio-safety cabinet class II. The un-
tightly closed LJ slopes were incubated in a slanted position for at 
least 24 hrs at 37ºC. All cultures were examined after 5-7 days of 
incubation for contaminations and rapid grower and thereafter weekly 
for positive growth for 4-6 weeks. Caps were opened once a week for 
a short interval to aerate the cultures. Cultures with no growth after 8 
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weeks of incubation were considered as negative growth. ZN stain, 
nitrate, catalase tests and Tellurite reduction were performed on  
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Kordofan 
Darfor 
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Gadaref 
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Khartoum 
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Fig 2.1 Sudan map showing sites of collection 
 Table 2.1: Quantitation scale recommended by the World Health 
Organization and the International Union Against Tuberculosis 
and Lung Disease 
Count on  Ziehl’s- Neelsen(100x) Report 
0 No AFB observed 
1-9/100 fields Exact count 
10-99/100 fields +1 
1-10/field +2 
> 10/field +3 
 
 
cultures positive for purposes of species identification. All positive 
cultures were stored at 4ºC for later use (WHO 1998). 
2.8.2.2.1. Digestion and decontamination of the samples 
The specimen was contaminated by more rapidly growing 
normal flora, these would rapidly overgrow the entire surface of the 
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medium and digest it before the tubercle bacilli start to grow, so the 
specimen was be subjected to digestion and decontamination 
procedures that liquefies the organic debris and eliminates the 
unwanted flora, (WHO 1998).  
2.8.2.2.1.1 Decontamination by 4% Sodium hydroxide (NaOH) 
A double volume of sodium hydroxide 4% was added to the 
sputum in a falcon tube mixed well and left to stand at room 
temperature for 15 min. Then the mixture was centrifuged at 3000xg 
for 15 min. The supernatant was discarded and also a double volume 
of distilled water was added and centrifuged again at 3000Xg for 5 
min. the supernatant was poured off and the sediment was ready for 
inoculation in the LJ media (WHO 1998, Della 2004). 
2.8.2.2.1.2 Decontamination in transit by 2% NaCl  
2% NaCl was added as much as possible to the specimen. Then 
the mixture was centrifuged at 3000xg for 15 min and left for 20 min. 
The supernatant was discarded and this step was repeated. The 
supernatant was poured off and 0.1 ML of the sediment was 
inoculated on the LJ media (Smithwick  et al 1975). 
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 2.8.2.2.2. Preparation of the Loweinstein Jensen media (LJ) 
The Lowenstein Jensen medium contains glycerol which 
favours the growth of Mycobacterium tuberculosis. The medium was 
prepared as follow; 37.4 g of LJ media was dissolved in 600mL 
distilled water, and then 12 mL of glycerol was added. The mixture 
was autoclaved at 1210C for 15 min. 1000 mL of homogenized fresh 
egg was added to the cooled media. The homogenized mixture was 
dispensed into Mc Mcartney bottles. The egg media were coagulated 
in heated inspissator (800C), the bottles were placed in a slanted 
position in the inspissator and coagulation occurred in 45 min at 800C. 
After inspissation, all the bottles of the media were incubated at 37 0C 
for 24 hours to check the sterility. The LJ medium was stored at 4 
0C(WHO 1998).  
2.8.2.2.3. Inoculation and incubation of the sample  
10 µl of the decontaminated sample was inoculated onto LJ 
medium and incubated at 37oC. The bottles were loosely tightened for 
24 hours to allow evaporation and then well tightened. Contamination 
was examined for 72 hours and less than one week to detect the rapid 
growers. The culture was examined weekly for the growth of 
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Mycobacterium tuberculosis for eight weeks. The contaminated 
bottles were discarded, and the one with growth was sub cultured for 
other purposes of biochemical and molecular identification (WHO 
1998, Gowan and Steel 1995). 
2.8.2.3. Antimicrobial susceptibility test 
2.8.2.3.1. Proportion method 
Drug sensitivity tests were performed of 240 isolates to 
isoniazid, streptomycin, rifampicin and ethambutol as described by 
(WHO 1998, Gowan and Steel 1995, Sunil et al 2004). LJ media with 
drug incorporated in various concentrations and plain medium for 
control were prepared. The bacterial serial dilutions suspensions were 
inoculation in the prepared LJmedia. The readings of the incubated 
samples were taken after 4 weeks and the second one was taken 6 
weeks. Resistance was calculated as the ratio of the number of 
colonies on the drug containing medium and those of control media. 
The isolates were considered as resistant if the ratio between the 
growth in the media containing the drugs and the growth in the control 
is greater or equal to 1% (WHO 1998, Sunil et al 2004). 
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2.8.2.3.2. Preparation of LJ media for drug susceptibility 
The LJ media for drug susceptibility (drug-containing medium 
and plane ones ) was prepared as mentioned above but containing a 
drug with the different concentrations (0.2 µg/mL for INH, 40 µg/mL 
for RIF, 4 µg/mL for SM and 2.0 µg/mL for ETH) (Kleeberg et al 
1980). 
2.8.2.3.3. Preparation of suspensions 
The suspensions were prepared by transferring loop full of 
bacterial growth from the culture by 10 µl loop into the suspension 
bottle containing sterile distil water . Homogenization was made by 
vortexing the bottle, the turbidity of suspension was adjusted to 
MacFarland standard No.1 by adding sterile distil water. Then two 
Serial dilutions were made from the original suspension of each 
sample (10-2 and 10-4).  
2.8.2.3.4. Inoculation and incubation 
The 10-2 suspension was subsequently inoculated on the drug-
containing medium. Two drug-free LJ slopes were inoculated with 10-
2 and 10-4 diluted suspensions. This was done for each sample tested.  
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The slopes were incubated at 37°C. The reading was taken after 
4 weeks and the second one was taken after 6 weeks. An isolate was 
considered resistant if the proportion of bacilli resistant to the critical 
concentration of a drug exceeded 1%.  
2.9 Biochemical methods 
2.9.1 680C Catalase test 
  Catalase is an intracellular, soluble enzyme capable of splitting 
of hydrogen peroxide into water and oxygen. The catalase activity was 
indicated by: 68 0C test at pH 7.0 (the activity of the enzyme affected 
by heating).  Two loop-full of 14 days old growth were suspended in 
0.5 ml buffer solution (appendix 4) in a screw cap tube, the second tube 
was used as the blank control (negative). The tubes were placed in a 
680C water bath for 20 min and were then cooled to room temperature. 
Then 0.5ml of freshly prepared tween peroxide (appendix 4) was 
added. The appearance of bubbles indicated a positive catalase test. The 
tubes were held for 20 min before being discarded as negative, the 
blank was also negative. M. tuberculosis is catalase negative (Vincent 
2003).  
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2.9.2 Nitrate test 
This test was done to detect the ability of Mycobacterium 
tuberculosis to reduce nitrate to nitrite. Two milliliters of nitrate 
buffer (appendix 4)  in screw-capped tubes were inoculated with 2 
loop full of each 4weeks old growth, and one tube left as a negative 
control containing no organism. The contents of the tubes were mixed 
well and then incubated at 370Cin incubator for 2hrs. After incubation, 
1 drop HCl, 2 drops of 0.2% sulfanilamide, and 2 drops 0.1% N-
naphthylethylene-diamine were added. The solutions were examined 
for the development of a pink/red color contrasting with the control. A 
pinch of powdered zinc was added to all the negative tubes to reduce 
nitrate to nitrite. The red color only after the addition of the zinc, 
confirmed a negative nitrate test M. tuberculosis and M. kansasii are 
nitrate reduction positive. However, M. bovis and M. intracellulare 
are nitrate reduction negative. (Tsukamura 1984, Vincent 2003).  
2.9.3 Tellurite reduction 
Four drops of Tellurite (appendix 4)  were added to each LJ 
growth cultures then incubated at 370C, and examined daily for seven 
days. A heavy black deposit appearing within seven days was positive 
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result, M. tuberculosis and M. bovis are tellurite positive (Tsukamura 
1984).  
2.10 Extraction of DNA 
Two loop full of M. tuberculosis was added to 400ul of sterile 
de-ionized water free from DNA and RNA in 1.5 screw cape tubes 
were then incubated in water bath at 1000C for 10 min, then 
centrifuged at 12000 g for 3 min. ( Hyeyoung et al 2000, Azar and 
Brazandeh  2005)  after that stored at  - 20 ºC till needed.  
2.11 Single step nested PCR based sequence analysis 
Single step nested PCR based sequence analysis using specific 
M. tuberculosis primers, was performed according to Kim (Kim et al 
2001) to amplify the rpoB gene in order to detect M. tuberculosis 
strains and determine their rifampicin susceptibility patterns. The 
assay targeted the rpoB gene at 205 bp with outer primers TB1 and 
TB2, and at 157 bp with the inner primers TB3 and TR8 (Kim et al 
2001). 
PCR reactions were performed in a PCR premix tubes 
(AccuPower PCR premix, bioneer) containing 2 U of Taq polymerase,  
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Table 2.2 sequence of the primer to amplify rpoB gene  
Primer Target bp Primer sequence 
TB1 205 5´ACG TGG AGG CGA TCA CAC ACC GCA GAC
GT 3´ 
TB2 205 5´TGCACG TCG CGG ACC TCC AGC CCG GCA
3´ 
TB3 157 5´ TCG CCG CGA TCA AGG AGT TCT TC 3´  
TR8 157 5´ TGC ACG TCG CGG ACC TCC A 3´ 
 
250 µM each deoxynucleotide triophosphate, 1.5 mM MgCl2, 10 X 
buffer contain (10 mM Tris HCL, 40 µM KCL), and gel loading dye. 
20 pmol of each primer was added (TB1, TB2, TB3 and TR8), the 
volumes were adjusted to 25 µl and 5 microliters of DNA was used as 
the template. The whole mixture was gently tapped to be evenly 
mixed. The reaction mixtures were subjected to 30 cycles of 
amplification (30 sec at 94o C, 30 sec at 72ºC and 30 sec at 72ºC) after 
an initial denaturation at 94oC for 5 min and final extension step at 74 
ºC for 10 min. 5 µl of the PCR products were visualized on 3% 
agarose gel stained with 5 % ethidium bromide and electrophoresed at 
80 V for 60 min and then was photographed.  The 25 µl of the PCR 
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product was stored at -20 ºC until sent for sequencing (Kim et al 
2001). 
2.12   3 %Agarose gel electrophoresis 
Efficient amplification was confirmed by gel electrophoresis on 
3% Agarose gel in a flask, (3g agarose + 100 ml 1X TBE buffer) the 
mixture was boiled till it completely dissolved, after cooling gel down 
to 60-70 ºC, 5 µl of ethidium bromide (0.5mg/ml) was added, then the 
100 ml of agarose was loaded without making air bubbles into the 100 
ml gel cast and was left for 30 minutes for polymerization. (Kim et al 
2001). 
The running buffer composed of 5ml of 10X TBE buffer and 
95ml of distilled water was poured in a gel cast. 10µl PCR product of 
each sample and the controls (Positive and negative) were  loaded into 
a well of agarose gel starting from lane 2 and 10µl DNA molecular 
weight marker 50 bp was loaded into lane 1.  Lastly, the tank was 
plugged into power supply and run at 80 volts for 60 minutes until 
loading buffer has moved sufficiently into the gel. The gel was 
illuminated with a Gel-Documentation System to visualization and 
documentation the PCR results (Kim et al 2001). 
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2.13 DNA Sequencing 
PCR amplified region of rpoB gene, were sequenced for all 
MTBC resistant isolates after amplification by single step nested PCR. 
Template DNA for PCR was prepared by boiling method as 
previously described. TB1 and TB2 primers were used to amplify 
205-pb and TB3 and TR8 primers were used to amplify 157pb rpoB 
gene containing 81-pb hot spot region of rpoB gene known to be 
associated with rifampicin resistance. The amplified rpoB genes were 
send to Korea for sequencing, sequencing was done commercially by 
Macrogene Company Seoul, Korea. 
The sequencing results were analyzed using Bioedit FASTA 
and CLUSTALW2 software programme.  
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 2.14 Statistical analysis 
- The demographic data and the convetional results were statistically 
analyzed using SPSSversion 16.0 software for windows. 
- The sequencing results were analysis using Bioedit software 
programme, and FASTA softwear   
http://fasta.bioch.virginia.edu/fasta_www2/fasta_www.cgi, 
- For phelogentic tree and blasting. 
http://blast.ncbi.nlm.nih.gov/Blast.cgi  and  http:// ncbi.nlm 
.nih.gov    
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Chapter Three  
Results  
3.1. Study population 
Four hundred and twenty specimens were collected (table 3.1). 
Only two hundred and forty two were included in the epidemiological 
study depending on microscopic and culture results.  
Table 3.1 Study population 
Area code Area  Samples size percentage 
1 Gadaref 48 11.4% 
2 Damazeen 30 7.1% 
3 Khartoum 45 10.7% 
4 Omdurman 59 14.0% 
5 Khartoum North 25 6.0% 
6 Kordafan 36 8.6% 
7 Darfor 22 5.2% 
8 Northern Sudan 25 6.0% 
9 S. Sudan 11 2.6% 
10 Gezera 66 15.7% 
11 kassala 53 12.6% 
total 11 420 100% 
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3.2. Epidemiological Results 
3.2.1. Age structure 
Four hundred and twenty patients with the age range from ≥ 15 
- ≤70 years were included in this study (mean 32.57 + 0.659, median 
30.00 and S. D 13.499). The distribution of the disease among 
different age groups is shown in Fig (3.1) and (Table 3.2). 
 
 
 
Fig.3.1. Age structure 
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Table  3.2 Age groups of the participants of the study by region 
Age in 
years 
Frequ
ency 
% 
 
Regions 
1 2 3 4 5 6 7 8 9 10 11 
≤15 - 19 38 9.1% 5 5 4 4 3 2 1 1 - 12 1 
20 - 24 78 18.6% 8 3 9 14 9 6 6 3 3 10 7 
25 - 29 76 18.1% 9 3 8 6 3 8 6 9 1 11 12 
30 - 34 42 10% 7 6 9 9 2 3 1 - 2 1 2 
35 - 39 48 11.4% 3 2 4 3 2 3 6 4 1 11 9 
40 - 44 43 10.2% 3 4 7 5 - 7 2 5 - 6 4 
45 – 49 29 6.9% 4 2 3 6 2 2 - - - 4 6 
50 – 54 25 6.0% 3 1 1 6 - - - 1 - 6 7 
55 - 59 6 1.4% 1 - - 2 - - - 1 - 1 1 
60 - 64 16 3.8% 1 1 - 1 1 5 - - - 3 4 
65 - ≥ 
70 
8 1.9% 3 1 - 3 - - - 1 - - - 
NA 11 2.6% 1 2 - - 3 - - - 4 1 - 
Total 420 100% 48 30 45 59 25 36 22 25 11 66 53 
 
1-Gadaref  2-Damazeen 3-Khartoum 4-Omdurman 5-Khartoum North 
 6-Kordafan     7-Darfor  8-Northern Sudan 9-Southern Sudan 10-Gezera 
 11-kassala 
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3.2.2. Gender  
Out of 420 patients who were enrolled in the study 284 (67.6%) 
were males while 136 (32.4%) were females (fig. 3.2). 
 
 
1-Gadaref      2- Damazeen  3- Khartoum   4-Omdurman   5- Khartoum North 
 6- Kordafan   7- Darfor    8- Northern Sudan  9- Southern Sudan   10- Gezera 
 11- kassala 
Fig. 3.2 The gender of patients 
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3.2.3. Marital status among the study subjects 
Two hundred and twenty two (52.9%) of patients were married 
while 148 (35.2%) were single, 21(5.0%) were widowed, 19 (4.5%) 
were divorced and 10 (2.4%) were missed (Fig.3.3).  
 
Fig 3.3. Marital status among the study subject  
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3.2.4 Clinical symptoms 
The consented patient's common complaint was cough, fatigue, 
headache, chest pain, shortness of breath, fever, loss of weight and 
haemoptysis. The cough was the most common complaint. (Table 
3.3). 
3.2.5. Duration of clinical symptoms 
The consented patients commonly complained of cough, fever 
and shortness of breath. The duration of these symptoms varied from 
two weeks to 48 weeks (but11 patients have the duration of their 
symptoms as follows; two patients 3years, two patients 2 years and 6 
patients less than 2years). 
3.2.6. Type of tuberculosis 
Out of four hundred and twenty 358(85.2%) were new TB case, 
42(10%) relapse 12(2.9%) default and were missed  8(1.9%). 
3.2.7. Treatment 
358 (85.2%) with no history of treatment, while 54(12.9%) 
received first line TB treatment and 8(1.9%) were missed.  
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Table 3.3. Clinical symptoms 
symptoms Frequen
cy 
% 
cough  66 15.7
cough + fever 173 41.2
cough + Fatigue 32 7.6 
cough + chest pain 31 7.4 
cough + Haemoptysis 4 1.0 
cough + shortness of breath 5 1.2 
cough +  loss of weight 11 2.6 
cough + night sweating 5 1.2 
cough + fever + Haemoptysis 7 1.7 
cough + fever + shortness of breath 59 14 
cough + fever + loss of weight 5 1.2 
cough + fever + fatigue 2 0.5 
cough + fever + headache 2 0.5 
cough + fever + night sweating                         2 0.5 
cough + chest pain + loss of weight 2 0.5 
cough + chest pain+ fatigue 1 0.2 
cough + loss of weight +Haemoptysis                        6 1.4 
cough + night sweating + loss of weight                        2 0.4 
missed 5 1.2 
Total 420 100.1 
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3.3. Socio-economic factors of the study subject   
3.3.1. Residence: 
The disease was found to be prevalent in all parts of the studied 
Sudan States. According to the residence of the patients, which, was 
classified as urban and rural, 265 (63.1%) were urban and 152 
(36.2%) were rural while 3 (0.7%) were missed. 
3.3.1.1 Types of housing 
 The kind of the residence of all patients was of different 
composition. 34 (8.1%) Concrete, 119(28.3%) built of brick, 146 
(34.8%) built of mud; the remaining houses were 106 (25.2%) 
Guteia,, 4(1.0%) brish, 2(0.5%) made of gras, and 9 (2.1%) was 
missed. 
3.3.2. Education 
Among the study population  143 (34.0%) patients were 
uneducated  and 27(6.4%) khalwa, while the educated vary in their 
education  from kuttab to university, only one (0.2%) kuttab, 
115(27.4%)  basic, 14 (3.3%) intermediate, 83 (19.8%) secondary, 
and 19 (1.1%)  were at university, and 18 (4.3%) was missed . 
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 3.3.3. Occupation 
It was found that out of the studied patients, 69 (16.4%) were 
housewives, 46 (11.0%) were students, 85(20.2%), 78(19.5%) were 
unemployed, 35(8.3%) were employed, 2(0.5%) were retired, 
20(4.8%) were farmers,  25(6.0%) were business persons(3.6% small 
business managers, 1.9% merchants and 0.5%  butchers), 63 (15.0%) 
were  labores,16 (3.8%) private sector, the remaining 11 (2.6%) 
including those who were 3(0.7%) mechanic, 1(0.2%) artist, 1(0.2%) 
painter and 6(1.4%) were shepherds while 8 (1.9%) were missed .  
3.3.4. Ethnic groups 
The patients belonged to different tribes from different parts of 
Sudan and 7(1.7%) were Ethiopian while 34(8.1%) were mised (table 
3.4)  
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Table 3.4 The ethnic group of the stuied patients  
Tribe frequence percent 
Denka 38  9.0 
Nuba 37  8.8 
Beni Amir 32 7.6 
Hawsa 26 6.1 
Ga'aly 19 4.5 
Falata 18 4.2 
Hadandwa 13 3.1 
Jawamaa 12  2.8 
Shygia  11  2.6 
Rashyda,Bargo, Kawahla, Mahas  8 for each 1.9 for each
Angassana, Bagara 7 for each 1.7 for each
Bariea, Hamar 6 for each 1.4 for each
Nuwear, Araki, Founj, Barta, Fur, Hassania 5 for each 1.2 for each
Tama, Shoulk, Donuglawi , Massaleet, Misserya 4 for each  1.0 for each
Broon, Barno, Bidaria, Meyama , Habbania 3 for each 0.7 for each
Zanda, Tinjarawi, Adok, Balanda, Dadania, 
Goraan, Mafaza, Gamrawi, Zagawa, Latoca 
Showehat, Marati, , Jaafari, Karsawi 
2 for each 0.5 for each
Faza, Dajow, Buzaa, boar toar, Aweel, Badi, 
Shokreia, Senigali, Salahabi, Raja, Rizaigat, 
Omeraney, Nefadi, Nomog, Musalamia, Moar, 
Toar Shoal, Maraweeb, Gawaweer, Gamooea, 
Hawari, Marateeb, Mari,  Horomo 
1 for each 0.2 for each
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3.3.5. Number of people per room 
The number of people per room varied between one to 13. The 
mean 2.80, the Std. error of mean 0.110, the median 3.0, S.D 2.250, 
variance 5.064 the minimum 1 and the maximum 13. (table 3.5). 
Table 3.5 Number of people per room 
Number of people \ room frequency percent 
1 14 3.3 
2 81 19.3 
3 82 19.5 
4 57 13.6 
5 41 9.8 
6 18 4.3 
7 15 3.6 
8 4 1.0 
9 5 1.2 
10 2 0.5 
11 0 0.0 
12 0 0.0 
13 1 0.2 
Missed 100 23.8 
Total 420 100.0 
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3.3.6. Type of food 
39(9.2%) of the studied patients depend only on Asseda in their 
food, 9(2.1%) Asseda and kissra, 70(16.7%) eat Kissra, 1(0.2%) 
Gurassa, 5(1.2%) Gurassa and Kissra and 229(54.5%) eat the common 
types of the Sudanese food, while 67(16.0%) were missed.  
3.3.7. Vaccination 
One hundred and sixty one (38.3%) of the studied patient were 
having Bacille Calmette-Guérin (BCG) vaccine while 203(48.3%) 
were not having any TB vaccine and 56(13.3%) were missed. 
3.4. Microscopic results 
Four hundred and twenty sputum samples from tuberculosis 
patients were examined and processed for indirect microscopic 
examination using ZN staining procedure. Three   hundred and ninty 
five (94.1%) of the examined specimens showed the characteristic 
AFB and they were considered as the true ZN positive, while twenty 
five (5.9%) were negative.  
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 3.5. Culture on LJ medium results 
All the collected samples (420) were cultured on LJ media, 
examination for the growth showed successful growth for 242 
(57.6%) samples, 109 (26.0%) failed to grow, and the remaining 69 
(16.4%) were contaminated. Out of the twenty five smears negative 
fifteen were able to grow and the remaining ten were excluded from 
the study (table.3.6). 
 
 
Table 3.6 Growth on LJ medium 
Growth 
on LJ 
Freq
uenc
y 
States  
%all 1 2 3 4 5 6 7 8 9 10 11
Growth 242 57.6 20 13 28 37 17 10 14 10 8 32 53 
No 
Growth
109 26.0 19 11 10 14 5 18 6 8 2 16 0 
Contam
ination 
69 16.4 9 6 8 8 3 8 2 7 1 18 0 
Total  100 48 30 46 59 25 36 22 25 11 66 53 
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3.6 Biochemical Analysis 
3.6.1 Catalase test  
Catalase test 68 oC labile, which was done for 242 isolates, 240 
(99.2%) isolates showed negative result and described as MTBC. The 
remaining two (0.8%) showed positive result. All MTBC were 68 oC 
labile catalase negative. 
3.6.2. Nitrate reduction test 
Out of 242 isolates, 207(85.5%) isolates produced pink colour 
(reduce nitrate to nitrite), which was the indicator of positive results, 
while 35(14.5%) were negative (no colour was produced), and by the 
addition of zinc dust the pink colour was developed confirming the 
negative results. The positive result indicates that the isolate might be 
M. tuberculosis, M. microti, or M. africanum, while the negative 
result related to M. bovis. 
3.6.3. Tellurite test 
The test was done for 242 isolates, 178 (73.6%) of them 
produced black metallic precipitate, and those were identified as M. 
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Tuberculosis or M. bovis, while 64(26.4%) strains were identified as 
M. microti or M. africanum. 
3.6.4 Identification of isolates Results 
Based on the molecular analysis and results of the three 
biochemical tests, Catalase, nitrate reduction and tellurite reduction 
out of 242 isolates 240(99.17%) isolates were M. tuberculosis 
complex (MTBC), and two(0.83%) isolates were identified as 
Mycobacterium other than Mycobacterium tuberculosis complex and 
were characterized as one isolate M. kansassi and the other 
characterized as M. avium. MTBC were characterized as 35(14.6%) 
isolates M. bovis, 143(59.6%) as M. tuberculosis and 62(25.8%) 
isolates as M. africanum or M. microti.  
3.7 Drug Susceptibility Testing Result (proportional method) 
The drug susceptibility test was done for only 242 isolates 
culture positive including two MOTT; M. kansassi was resistant to 
RIF and INH. Out of 240 culture positive MTBC, 34 (14.17%) were 
resistant to RIF, 27 (11.25%) were resistant to INH and 24 (10.74%) 
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were resistant to STM while 17 (7.08%) were resistant to ETH. (table 
3.7, 3.8 , 3.9 & 3.10 ) 
 
Table 3.7 Single and multiple drug resistance patterns of MTBC 
isolates 
Drug No. of strains resistant % of 240 isolates 
STM 24 10 
RIF 34 14.17 
INH 27 11.25 
ETH 17 7.08 
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Table 3 . 8 Drug susceptibility result and resistance profiles - 
Resistance pattern of the first line anti-tuberculous drugs  
A
re
a 
Sa
m
pl
es
 si
ze
 
G
ro
w
th
  o
n 
L
J 
 Resistance 
IN
H
 
R
IF
 
ST
R
 
E
T
H
 
RIF
STR
INH 
STR
ETH
STR
INH
ETH
INH
RIF
 
ETH
RIF 
 
STR 
ETH
RIF 
 
STR 
ETH 
INH 
 
STR 
INH 
RIF 
 
ETH
RIF 
INH
 
STR
ETH
RIF 
INH
1 48(11.4%
)
20(41.7%
)
- - - - 1(2.5%
) 
- - - 1(2.5%
). 
- - - - - 1(2.5%
) 
2 30(7.1%
)
13(43.3%
)
- 1(2.5%
) 
- - - - - - - - - - - - 1(2.5%
) 
3 
45(10.7%
)
28(62.2%
)
- - - - - - - - 1(2.5%
) 
1(2.5%
) 
1(2.5%
) 
- - 1(2.5%
) 
- 
4 
59(14.0%
)
37(62.7%
)
- - - - 1(2.5%
). 
- - - 2(4.8%
) 
- - - 2(4.8%
) 
- - 
5 25(6.0%
)
17(68%
)
- - - - - - - - - - - - 1(2.5%
) - - 
6 
36(8.6%
)
10(27.8%
)
- - - - - - - - - - - 1(2.5%
) 
1(2.5%
) 
- - 
7 
22(5.2%
)
14(63.64%
)
- - - - - - - - - - 1(2.5%
) 
- - - - 
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Continue Table 3. 8 
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8 25(6.0%
)
10(40%
)
- - - - - - - - 
2(4.8%
) 
- - - - - - 
9 11(2.6%
)
8(72.73%
)
- - - - - - - - - - - - - - 
1(2.5%
). 
10 66(15.7%
) 
32(48.48%
)
- - - - - - - - 
1(2.5%
) 
- - - 
1(2.5%
) 
- - 
11 53(12.6%
) 
51(100%
)
3(6.1%
) 
5(10.2%
)
3(6.1%
) 
2(4.8%
) 
4(8.2%
) 
2(4.8%
) 
1(2.5%
) 
3(6.1%
) 
- 
1(2.5%
) 
- - - 
1(2.5%
) 
1(2.5%
) 
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l 420 
240 
3(6.1%
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6(12.3%
)
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) 
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3(6.1%
) 
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) 
2(4.8%
) 
1(2.5%
) 
5(10.2%
) 
2(4.8%
) 
4(8.2%
) 
%
 
- 57.1 
1.2%
 
2.5%
1.2%
1. 
0.8 %
 
2.5%
 
0.8 %
 
0.4 %
 
1.3%
 
2.9%
 
0.8 %
 
0.8 %
 
0.4 %
 
2.1%
 
0.8 %
 
1.7%
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Table 3. 9 Drug susceptibility results of the first line anti-
tuberculous drugs  
Area Samples size Growth on LJ
medium 
 
DST results 
sensitive resistance 
1 48(11.4%) 20(41.7%) 17(85%) 3(15%) 
2 30(7.1%) 13(43.3%) 11(84.6%) 2(15.4%) 
3 45(10.7%) 28(62.2%) 24(85.7%) 4(14.3%) 
4 59(14.0%) 37(62.7%) 32(86.5%) 5(13.5%) 
5 25(6.0%) 17(68%) 16(94.1%) 1(5.9%) 
6 36(8.6%) 10(27.8%) 8(80%) 2(20%) 
7 22(5.2%) 14(63.64%) 13(92.9%) 1(7.1%) 
8 25(6.0%) 10(40%) 8(80%) 2(20%) 
9 11(2.6%) 8(72.73%) 7(87.5%) 1(2.5%) 
10 66(15.7%) 32(48.48%) 30(93.8%) 2(6.2%) 
11 53(12.6%) 53(100%) 27(50.9%) 26(49.1%) 
Total 420 242(57.62%) 193(79.75%) 49(20.25%)
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Table 3.10 Sensitivity test of the MTB isolates to first line anti-
tuberculous drugs 
Drug susceptibility No. of isolate % 
  Sensitive 192 80 
Resistance 48 20 
Resistant to one drug 14 29.2 
Resistant to two drugs 25 41.7 
Resistant to three drugs 10 20.8 
Resistant to four drugs 4 08.3 
Total 240 100 
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3.8. Molecular Biology Results 
3.8.1 Nested PCR based sequence analysis results 
3.8.1.1 Amplification of rpoB gene by single step Nested PCR 
Amplification of the rpoB gene of the clinical isolates targeted 
205bp and 157 bp were successfully done (fig.3.4, 3.5 & 3.6) 
confirming that all the isolates were M. tuberculosis species and were 
sent for the sequencing. 
 
 
 
 
Fig. 3.4. Showing amplification of the rpoB gene of the clinical 
isolates targeted 205bp and 157 bp 
MWM
205bp   
157bp100bp 
200bp 
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Fig. 3.6 Showing amplification of the rpoB gene of the clinical 
isolates targeted 205bp and 157 bp 
 
 
 
205bp    
205bp   
157bp  
157bp 
  200bp 
200bp 
100bp   
100bp   
4 3 65 82   971 10 11 12 
12 1110987654 3 2   1 
Fig. 3.5 Showing amplification of the rpoB gene of the  
clinical isolates targeted 205bp and 157 bp 
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3.8.1.2 Analysis of generated nucleotide sequences  
Using clustalw2 method (http://www.ebi.ac.uk)  and Boxshade 
server 3.21, www.ch.embnet.org/software/BOX_form.html the 
generated nucleotide were alignment (fig.3.7(appendex 1) and 
compared pairwise for similarity using    
http://fasta.bioch.virginia.edu/fasta_www2/fasta_www.cgi. The 
nucleotide sequences were blasted for confirmation using Error! 
Hyperlink reference not valid. .  The bioedit software was used to determine 
the C+G% content and were found 64.44%→65.77%. (table 3.11). 
3.8.1.3 Analysis of rpoB gene mutations 
Alignment of the DNA fragment rpoB was carried out and 
compared with rpoB gene of reference strain H37RV Using BLAST 2 
sequence program for DNA sequence comparisons, Error!  Hyperlink 
reference  not  valid. .  The phylogenetic tree showed close relationship 
between the strains (fig. 3.9) In 34 rifampicin resistant strain (14.9%), 
ten mutations (30.3%) were identified localized in 81 bp RRDR 
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(Rifampicin Resistant Determination Region) or hot spot region of 
rpoB gene associated with rifampicin resistance. Most frequent 
mutated codons were codon 526 (four (40%) (CAC→AAC / His → 
Asn, CAC→GAC/ His → Asp, CAC→ CGC /His → Arg,   CAC→ 
CTC/His → Leu) and codon 531(TCG→TTG/ Ser → Leu). And two 
(20%) point of mutations in amino acid were detected in codon 
516(GAC→GTC/ Asp → Val & GAC→GAA/ Asp → Glu) ( table 
3.12 & fig 3.8)  
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Table 3.11 C+G % of the resistant isolates 
Nucleotide 
length 
C + 
G 
C + G 
% 
Frequency Nucleotide 
change    
149 98 65.77 21 - 
149 97 65.10 4 C→T 
149 96 64.43 1 2(C→A) 
149 99 66.44 1 A→G 
109 70 64.22 1 - 
112 
 
 Table 3.12 Data and mutations in 81‐bp region of the rpoB gene in nine M. tuberculosis MDR isolates 
Amino acid change   nucleotide change   frequency          DST                codon 
INH  RIF   STR   ETH 
Isolates no.  treatment receivedAge    gender    Area     TB case 
                                                          
Asp → Val                          GAC → GTC         1(10%) R        R      R        S      516                484                   None 40    Male         KHN              New 
Asp → Glu                         GAC → GAA         1(10%) R        R       S       R         815                        None 23    Female     Kassala        New 
His  → Leu                         CAC → CTC           1(10%) 
His  → Arg                         CAC → CGC          1(10%) 
His  → Asp                         CAC → GAC           1(10%) 
S        R        R      R       526 
R        R        R      S 
R        R        R      S 
34                          None 
33                          None 
142                        First line 
35   Male        Kassala          New 
42   Male        kassala          New 
27   Male        Omdurman   Old 
His  → Asn                         CAC → AAC           1(10%) 
 
 
Ser → Leu                          TCG → TTG           4(40%) 
Ser → Leu                          TCG → TTG 
Ser → Leu                          TCG → TTG 
Ser → Leu                          TCG → TTG 
 
R         R       S      R 
 
 
R        R        R     R      531 
R        R        R     R 
R        R        R     R 
R        R        R     R 
815                        None 
 
 
313                        First line 
145                        None 
159                        First line 
32                          None 
23   Female    kassala          New 
 
 
65   Male       Gadarif          Old 
43    Male       Damazeen     
New 
21   Female    S. Sudan        Old 
24   Male        kassala          New 
KHN – Khartoum North                           His ‐   histadine 
Val ‐ valine                                                 Leu ‐  leucine 
Arg  ‐  arginine                                          Asn‐ asparagines  
Asp ‐   aspartic acid                                  Glu ‐  glutamine  
Ser ‐  serine                                                                
       
 
113 
 
 3.7 Alignment of proteins of isolates showing the change in the 
proteins 
 
E = Glutamine,  S = Serine,   L= Leucine,  D = Asparagine,  = Asn , R 
= Arganine,  V = Valine,  H = Histadine 
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Fig. 3.8 The phylogenetic tree of the resistant strains   
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Chapter four 
Discussion 
 
Tuberculosis is an ancient disease causing great concern in 
resource rich and resource poor countries alike. In recent years 
infection with M. tuberculosis has been complicated by the 
development of multidrug resistance (Espinal et al 2001). It can be 
predicted that poor case-holding, non-adherence, combined with 
overstrained and inadequately funded TB control programmes in the 
advent of AIDS, may result in the emergence of increased numbers of 
resistant strains. If these spread in a community, TB may become 
progressively uncontrollable using the current efficient, cheap, and 
cost effective drugs. 
The poor and under-serviced rural areas, makes Sudan a fertile 
ground for the TB to flourish. The total number of the findings 
received by (SNTBCP) by the end of 2009, new cases were as 
follows; 10263smear positive, 6135 smear negative, 4526 extra-
pulmonary and not done 1097. The total cases by the end of second 
116 
 
quarter of 2010 were 54086 (NTBSCP 2009 & 2010). The low 
national income and the meagre resources resulted in poor health 
service to needy communities. The civil war and the displacement of 
population have complicated the health problems and helped the 
spread of infectious diseases in the different parts of the country. 
Although tuberculosis is known to be endemic in Sudan, little 
information is available about the burden of the disease, its 
epidemiology or the extents of drug resistance problem are not well 
described (El Sony et al 2000). 
The aim of this work was to study the genetic diversity of drug 
resistance pattern of the M. tuberculosis and to map the drug 
resistance pattern of mycobacteria isolates from pulmonary TB 
patients from eight regions of Sudan, using conventional and genetic 
methods. Conventional laboratory methods used for diagnosis of the 
tuberculosis have inherent limitation, but molecular techniques can 
provide useful data. 
The first phase of the study involved the collection of the 
epidemiological data and samples.  Many problems were encountered 
in this stage; few saliva specimens were collected instead of sputum 
117 
 
since information regarding the procedure of collecting samples was 
not adequately followed by patients. Many of the samples turned to be 
culture negative as they were obviously collected after the treatment 
was initiated. Concerning growth there were two problems due to 
media transportation; the first one was that there was no growth and 
this problem was solved by decreasing the storage time to one week, 
the second was the high percentage of contamination, and this 
problem was solved by changing the decontamination method from 
2% Sodium chloride to 4% Sodium hydroxide. 
The data obtained from the enrolled patients revealed that 
tuberculosis was distributed in most regions of Sudan, but Khartoum, 
Madani, Kassala and Gadarif had the highest rate of tuberculosis 
infection in the study group study, (129 [30.7%], 66 [15.7%], 53 
[12.6%], and 48 [11.9%] ) respectively. 
Tuberculosis was distributed among almost all Sudanese tribes 
with varying rates, but the higher incidence rates were Denka38 
[9.0%],  Nuba (37 [8.8%], Beni Amir (32 [7.6%], Gaalin (19 [4.5%], 
Falata (18 [4.2%], and Shygia (11 [2.6%]. EL Eraggi (2004) reported 
the infection distribution among the majority of the tribes with 
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varying rates where the tribe of Denka (12.9%), Gaalin (12.2%), and 
Nuba (10.9%) were the most represented than other tribes.  Khalid 
(2010) reported that a higher prevalence in Beni Amir tribe (37%) and 
Hadandwa (31.7%). These two tribes are affected due to the low level 
of education, illiteracy and low income, which are known risk factors 
for TB infection that could also result in delay in seeking TB 
Treatment. The possibility in genetic predisposition of members of 
these tribes should be considered, since many reports worldwide 
reported gentic susceplity to TB infection (Abel and Casanova 2000, 
Bellamy et al 2000, Comstock 1978). 
In most countries, more cases of TB were partially reported 
among men than women. In this study gender was investigated and 
showed that TB among males 284 (67.6%) was higher than in females 
136 (32.4%), which agreed with Khalid (2010), El Sony et al (2003). 
This difference is partly due to the fact that women have less access to 
diagnostic facilities in some settings, but the broader pattern also 
reflects real epidemiological differences between men and women, 
both in exposure to infection and in susceptibility to disease, and may 
be also attributed to the fact that an X- chromosome susceptibility 
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gene may contribute to excess of males with tuberculosis observed in 
many populations, as reported by Bellamy (2000). 
   This study showed that TB infection was distributed among all 
age groups (≥15- ≤70 years) but with varying frequencies (mean 32.57 
and Std. deviation 13.499). The maximum risk of infection was 
among age groups (20-24) 78(18.6%) and (25-29) were 76(18.1%), 
and the lower rates the age group (55-59) were 6 (1.4%) and (65-70) 
were 8(1.9%).  Infected patients under 50 years were (84.3%). Similar 
TB age distribution was reported by Murray et al (1990). Furthermore 
WHO 2008 reported in developing countries 80% of TB patients 
under the age of 50 years. Borgdorff et al (2000) reported that in 
regions where the transmission has been stable or increasing for many 
years the incidence rate was highest among young adults.  As 
transmission falls, the caseload shift to the older age groups and a 
higher proportion of cases come from the reactivation of latent 
infection. 
In this study the marital status of the enrolled patients was 
investigated (35.2%) were single and (52.9%) were married, and the 
close contact with the smear positive patients exposed the whole 
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family to maximum risk of infection. 70% of the married patients 
were males who were responsible for the financial support of the 
family, this reflects the negative impact of the disease on social and 
economical status. 
The kind of residence of the participants varied in its 
composition but (61.5%) of them lived in simple houses made of 
straw, grass and mud with little ventilation, and moisture which 
increases the risk of transmission of TB disease.    
This study found that, among the studied population 63.1% 
lived in urban and 36.2% in rural. 34% were uneducated, 27.4% were 
basically educated and only 1.1% were university gradude. This study 
found that 67.4%  of the participants of this study were in low income  
occupations, ( housewives, students, unemployed, retired, famers and 
labouers) and that agree with Horwitz (1970) and Lowell (1976) who 
reported the inverse relationship between the socioeconomic status 
and TB morbidity beside other factors such as (racial differences, 
overcrowding  of poor and ill-nourished people and availability of 
health care which continues to produce a relatively high incidence of 
the disease owing to a greater ease of transmission of the infection  ) 
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   This study found that 34.2% of patients lived together with 
more than three persons in the same room, the close contact with the 
smear positive patients is one of the maximum risk factors for the 
transmission of pulmonary TB as reported by (Dye et al 1999, Castelo 
et al 2004, WHO 2006) Tuberculosis is a disease with deep social and 
economical roots. Low-income people with large families, living in 
dense urban communities with deficient housing conditions, have a 
high probability of becoming infected, developing active disease, and 
dying from TB.  
This study revealed that TB was widely spread in almost the 
whole study area. 85.2% of the investigated patients were new cases 
with no history of  treatment, while 12.9% had received first line TB 
treatment and were classified as 10% were relapsed and 2.9% were 
defaulters, reflecting the active transmission of TB, the relapsed and 
re-infection could be due to inadequate or intermittent therapy 
(Shoudhury et al 1997).  
Eligible patients included in this study were diagnosed as TB 
patients (AFB positive).Twenty five specimens were negative by 
indirect AFB although they were diagnosed as TB smear positive 
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patients. Fifteen were culture positive and ten were culture negative, 
so they were excluded from the study.  
Culture is still considered the gold standard for diagnosis of 
tuberculosis (Schrim et al 1995). In this study only (57.6%) out of 420 
specimens showed a successful growth, 26% failed to grow, and the 
remaining 16.4% were contaminated.  The low rate of growth may be 
due to hard decontamination (4% NaOH), and the high number of 
culture negative samples raised some serious concern about the 
quality of the specimens collected.  In fact the quality of collected 
samples was so poor, it is therefore imperative for any research to 
implement, quality control for the sample collection (Lan et al 1999, 
Addo et al 2002). 
Biochemical test and molecular analysis confirmed 240 isolates 
as MTBC; 59.6% M. tuberculosis, 14.6% M. bovis, 25.8% M. 
africanum or M. microti. Two isolates as MOTT were characterized as 
M. Kansasii (Hass et al 1999) and M. avium which is often associated 
with HIV infection (Metchcock et al 1995).  The proportion of 
Tuberculosis burden caused by different species of Mycobacterium in 
Sudan is not well known. 
123 
 
Drug susceptibility test in this study showed that 11.3% was 
INH resistant to 0.2 mg/ml of the drug (5% primary and 6.3% 
acquired resistance). 14.9% were resistance to RIF (5.8% primary and 
8.4% acquired). Resistance to antituberculous drugs is an emerging 
global health problem (Ariel pablos and Mendez et al 1998), and this 
may be due to inadequate therapy or poor drug absorption (Jacobs 
1994). Drug resistance was reported in Sudan by El Eragi (2004) and 
Khalid (2010) who reported that 56.5% resistant to RIF was observed.  
DNA sequence of 28 isolates revealed that nineteen resistant 
isolates carried no mutation within the 81 bp core region, this point to 
the possible existence of other mechanisms of resistance or functional 
mutations outside the analysed region and similar results were 
reported by Afanas et al (2006) and in Japan Sekiguchi et al (2007) 
and in Sudan Khalid (2010) found that no mutations were observed in 
four resistant isolates.   
26.5% of the RIF resistant MTBC had mutation within 81-bp 
hot spot region of rpoB gene (RRDR) corresponding to codon 507- 
533 (Sekiguchi et al 2007). All the mutant strains carried mutations at 
known sites (codons 516, 526 and 531). One strain (10 %) carried 
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double missense mutations.  Mutations at codon 531 occur at a 
relatively higher frequency, but different groups have reported 
disproportionate frequencies of mutations at these codons. Groups 
working in Greece (Matsiota et al 1998), Germany, Sierra Leone 
(Rinder et al 1997), (Pozzi et al 1999) and South Africa -KwaZulu-
Natal (Kiepiela et al 1998) have reported differences in the relative 
abundance of these mutations among rifampicin-resistant M. 
tuberculosis. In addition, the frequency of Ser531Leu remains the 
most common in isolates with a resistant phenotype and this agree 
with the results of this study, the frequency of Ser531Leu / 
TCG→TTG were found to be 40%. And in Sudan El Eragi (2004) 
found the rate of this mutation was 54.55%. 
Nucleotide substitutions observed at codons 516, 526 and 531 
were in association with point mutations at other codons. The 
involvement of codons 516 (two (20%) GAC→GTC/ Asp → Val & 
GAC→GAA/ Asp → Glu), 526 (four (40%) (CAC→AAC / His → 
Asn, CAC→GAC/ His → Asp, CAC→ CGC /His → Arg,   CAC→ 
CTC/His → Leu), and 531 (four (40%) occurred at a frequency of 
20%, 40%, and 40%, respectively. Studies conducted between 1996 
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and 1997 within communities in and around Managing(  South Africa) 
have shown the presence of the Ser531Leu, His526Tyr, His526Asp, 
and Asp516Val mutations in 44%, 10%, and 10 % of RIF -resistant 
isolates, respectively (Van der Spoel 2001). The results of this study 
showed that the widely reported mutations predominate in the nine 
strains, but the frequency of each determinant seems to be in 
concordance with the disproportionate geographical distribution as 
reported by Rinder et al (1997). Identical changes in amino acids were 
detected by (Mani et al 2001, Schilke et al 1999, Pozzi et al 1999, 
Valim et al 2000). 
The phylogenetic analysis of the rpoB gene sequence of M. 
tuberculosis strains revealed the existence of sequence divergence 
among the studied strains. They were divided into five major clusters 
(fig. 3.9): cluster A (19isolates), which shared a similar rpoB 
sequence, cluster B (1isolate), cluster C (4 isolates, which were 
resistance to the four drugs), cluster D (2 isolates) and cluster E (2 
isolates). The rpoB sequence similarities within each cluster (94% in 
cluster A, 100% in cluster B, 100% in cluster C), finding of the results 
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exert low transmission. However no diversity had been recognized in 
clusters B and C. 
  Cluster A, C, and D, consist of isolates from different regions 
of Sudan. Cluster C, contained the identical mutation (Ser531 Leu / 
TCG→TTG) but they were from four different regions (Gadarif. 
Kassala, Damazin and S. Sudan) and this may be due to the spread of 
particular strain in wide geographical areas.  Cluster C contained one 
mutation that changed to coded protein (CAC His →AAC/ Asn -
Kassala, GAC/ Asp -Omdurman, CGC / Arg - Kassala and   CTC/ 
Leu- Kassala) and this reflects the high diversity of Mycobacterium 
Tuberculosis strains within Kassala. Although the isolates in cluster D 
were from the same area (Kassala) they were low diverted and this 
due to the fact that one strain contains double mutations (Asp516 → 
Glu/ GAC → GAA and His526 → Asn /CAC → AAC) while the 
other contain single mutation (His526 → Asp/ CAC → GAC). 
Isolates from Kassala region showed more diversity since different 
strains were distributed in four major clusters and this may be due  to 
high transmission rate and active migration from  neighbouring 
countries  and movement of the population in and out the region .  
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The phylogenetic tree showed close relationship between 
resistant strains and this agree with Brosch et al (2002) and Kim et al 
(1999).  
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Conclusions and Recommendations 
Conclusions 
1- The present study concluded that the pulmonary tuberculosis 
disease is prevalent in all studied regions of Sudan, affecting 
both males and females belonging to several Sudanese tribes at 
all age groups specially the young adults. 
2- Infection with both Mycobacterium tuberculosis and MOTT 
were recognized with similar symptoms. 
3- This study analyzed Mycobacterium tuberculosis complex 
isolates from nine states and found that Mycobacterium 
tuberculosis was the dominant cause of pulmonary TB in Sudan 
4- . In this study the drug resistance rate was 20% and multidrug 
resistant was 7.5%, however, this result was the first to 
represent the national resistance rate which is alarming.  
5- Isolates from Kassala showed the highest drug resistance rate 
(49.1%) while Khartoum showed the highest multidrug 
resistant rate (2.9%).  
6- Resistance to the first line anti tuberculous drugs was detected 
and RIF registered the highest rate (14.9%). High prevalence of 
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resistance to rifampicin was associated with various point 
mutations in the 81-bp core region of the rpoB gene.  
7- The phylogenetic analysis showed strong relationship between 
the Mycobacterium tuberculosis resistant strains in Sudan, 
suggesting a common source of resistance. 
 
Recommendations  
1- National drug resistance surveillance is needed to analyze more 
samples from other states.  
2- Molecular methods are important for early detection of MDR-
TB to control and interrupt the transmission. 
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Appendix 1 
 
                                                 
H37-81-RRDR          GGCACCAGCCAGCTGAGCCAATTCATGGACCAGAACAACCCGCTGTCGGGGTTGACCCACAAGCGCCGACTGTCGGCGCTGG 
3-TB1  TCAAGGAGTTCTTCGGCACCAGCCAGCTGAGCCAATTCATGGACCAGAACAACCCGCTGTCGGGGTTGACCCACAAGCGCCGACTGTCGGCGCTGGGGCCCGGCGG 
6-TB1  TCAAGGAGTTCTTCGGCACCAGCCAGCTGAGCCAATTCATGGACCAGAACAACCCGCTGTCGGGGTTGACCCACAAGCGCCGACTGTCGGCGCTGGGGCCCGGCGG 
H37    TCAAGGAGTTCTTCGGCACCAGCCAGCTGAGCCAATTCATGGACCAGAACAACCCGCTGTCGGGGTTGACCCACAAGCGCCGACTGTCGGCGCTGGGGCCCGGCGG 
1-TB1  TCAAGGAGTTCTTCGGCACCAGCCAGCTGAGCCAATTCATGGACCAGAACAACCCGCTGTCGGGGTTGACCCACAAGCGCCGACTGTCGGCGCTGGGGCCCGGCGG 
4-TB1  TCAAGGAGTTCTTCGGCACCAGCCAGCTGAGCCAATTCATGGACCAGAACAACCCGCTGTCGGGGTTGACCCACAAGCGCCGACTGTCGGCGCTGGGGCCCGGCGG 
17-TB1 TCAAGGAGTTCTTCGGCACCAGCCAGCTGAGCCAATTCATGGACCAGAACAACCCGCTGTCGGGGTTGACCCACAAGCGCCGACTGTCGGCGCTGGGGCCCGGCGG 
18-TB1 TCAAGGAGTTCTTCGGCACCAGCCAGCTGAGCCAATTCATGGACCAGAACAACCCGCTGTCGGGGTTGACCCACAAGCGCCGACTGTCGGCGCTGGGGCCCGGCGG 
19-TB1 TCAAGGAGTTCTTCGGCACCAGCCAGCTGAGCCAATTCATGGACCAGAACAACCCGCTGTCGGGGTTGACCCACAAGCGCCGACTGTCGGCGCTGGGGCCCGGCGG 
21-TB1 TCAAGGAGTTCTTCGGCACCAGCCAGCTGAGCCAATTCATGGACCAGAACAACCCGCTGTCGGGGTTGACCCACAAGCGCCGACTGTCGGCGCTGGGGCCCGGCGG 
23-TB1 TCAAGGAGTTCTTCGGCACCAGCCAGCTGAGCCAATTCATGGACCAGAACAACCCGCTGTCGGGGTTGACCCACAAGCGCCGACTGTCGGCGCTGGGGCCCGGCGG 
28-TB1 TCAAGGAGTTCTTCGGCACCAGCCAGCTGAGCCAATTCATGGACCAGAACAACCCGCTGTCGGGGTTGACCCACAAGCGCCGACTGTCGGCGCTGGGGCCCGGCGG 
30-TB1 TCAAGGAGTTCTTCGGCACCAGCCAGCTGAGCCAATTCATGGACCAGAACAACCCGCTGTCGGGGTTGACCCACAAGCGCCGACTGTCGGCGCTGGGGCCCGGCGG 
15-TB1 TCAAGGAGTTCTTCGGCACCAGCCAGCTGAGCCAATTCATGGTCCAGAACAACCCGCTGTCGGGGTTGACCCACAAGCGCCGACTGTCGGCGCTGGGGCCCGGCGG 
16-TB1 TCAAGGAGTTCTTCGGCACCAGCCAGCTGAGCCAATTCATGGACCAGAACAACCCGCTGTCGGGGTTGACCCACAAGCGCCGACTGTTGGCGCTGGGGCCCGGCGG 
22-TB1 TCAAGGAGTTCTTCGGCACCAGCCAGCTGAGCCAATTCATGGACCAGAACAACCCGCTGTCGGGGTTGACCCACAAGCGCCGACTGTTGGCGCTGGGGCCCGGCGG 
24-TB1 TCAAGGAGTTCTTCGGCACCAGCCAGCTGAGCCAATTCATGGACCAGAACAACCCGCTGTCGGGGTTGACCCACAAGCGCCGACTGTCGGCGCTGGGGCCCGGCGG 
27-TB1 TCAAGGAGTTCTTCGGCACCAGCCAGCTGAGCCAATTCATGGACCAGAACAACCCGCTGTCGGGGTTGACCCACAAGCGCCGACTGTCGGCGCTGGGGCCCGGCGG 
29-TB1 TCAAGGAGTTCTTCGGCACCAGCCAGCTGAGCCAATTCATGGACCAGAACAACCCGCTGTCGGGGTTGACCCACAAGCGCCGACTGTCGGCGCTGGGGCCCGGCGG 
31-TB1 TCAAGGAGTTCTTCGGCACCAGCCAGCTGAGCCAATTCATGGACCAGAACAACCCGCTGTCGGGGTTGACCCACAAGCGCCGACTGTTGGCGCTGGGGCCCGGCGG 
32-TB1 TCAAGGAGTTCTTCGGCACCAGCCAGCTGAGCCAATTCATGGACCAGAACAACCCGCTGTCGGGGTTGACCCACAAGCGCCGACTGTTGGCGCTGGGGCCCGGCGG 
33-TB1 TCAAGGAGTTCTTCGGCACCAGCCAGCTGAGCCAATTCATGGACCAGAACAACCCGCTGTCGGGGTTGACCCGCAAGCGCCGACTGTCGGCGCTGGGGCCCGGCGG 
34-TB1 TCAAGGAGTTCTTCGGCACCAGCCAGCTGAGCCAATTCATGGACCAGAACAACCCGCTGTCGGGGTTGACCCTCAAGCGCCGACTGTCGGCGCTGGGGCCCGGCGG 
25-TB1 TCAAGGAGTTCTTCGGCACCAGCCAGCTGAGCCAATTCATGGACCAGAACAACCCGCTGTCGGGGTTGACCGACAAGCGCCGACTGTCGGCGCTGGGGCCCGGCGG 
36-TB1 TCAAGGAGTTCTTCGGCACCAGCCAGCTGAGCCAATTCATGGAACAGAACAACCCGCTGTCGGGGTTGACCAACAAGCGCCGACTGTCGGCGCTGGGGCCCGGCGG 
 
Fig.3.9 The alignment of rpoB gene sequencing, using boxshade software version 3.12  
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Appendix 2 
National Health Laboratory – TB Research Unit 
Study On: Molecular diversity of drug resistance patterns of 
Mycobacterium tuberculosis isolates from different regions of 
Sudan 
QUESTIONNAIRE 
PATIENT IDENTITY 
Date……………………………………Code…………………….  
State……………City/Village……………….Sheikh …………...   
Health center ……………………….      Unit …………………….. 
Card number ……………………….     Date registered………….. 
Name of patient ……………………………………...…………… 
Sex:          M         F           Age ……………   tribe ….…………...  
Marital status:        single             married               divorced                 
widowed                      
Education:        non        primary        secondary         graduated             
post graduated 
Occupation:         employed           unemployed         retired            
student         housing 
Types of house:       shutter house       mud house         breaks house         
concrete 
Number of people/room …………………………………………...   
Annual level of income /pound………………….…………………   
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Types of food ……………………………………………………... 
Address…………………………..Telephone……………………… 
What complain caused you to seek care? 
…………………………………………… 
         Symptom                          Yes               No                        Duration    
Cough                             …….                …….           ……………… 
Weight Loss                   …….                …….            ..…...……….. 
Fatigue                           …….                …….              .…...……….. 
Anorexia                        …….                …….               …...……….. 
Fever                              …….                …….                ......……….. 
Night sweats                  …….                …….               …...……….. 
Chest pain                      …….                …….               …...……….. 
Headache                       …….                …….               …...……….. 
Haemoptysis                  …….                …….                ……. ……..   
Other………………………………………………………………… 
General appearance:      good           satisfactory                 poor 
Weight/Kg ………………………   Height/cm …………………… 
                           BCG scar:          absent                   present 
Contact of index case (TB):        household              community                            
unknown 
Types of TB of contact:       new case        relapse        default             
treatment failure  
Lab tests and other investigations:  
Date of first complaints ………………………………………………... 
Date of sampling ……………………………………………………… 
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Results of AFB :          Negative                 positive  
   X-rays:                     done              not done    if done/ date ……...         
        Cavity          fibrosis          infiltrates           pneumothorax 
         Pleural effusion           disseminated             tuberculoma                                   
Other CXR finding    such as: ……………………………………… 
Treatment:  Date of first care…………………………….………... 
 
Treatment received:      INH           RIF          EMB         STM              
                                         PZA        AMK         CM           CS 
                                         THZ          KM          CFZ          CLR                        
                                         CPX\LFX\OFX\SPX         AMX-CLV                               
 
Others: Such  as……………………..…………………………...… 
………………………………………………………………………. 
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 3 xidneppA
 
 (اﺳﺘﺎك)اﻟﻤﺘﻮﻃﻨﺔ و اﻟﻤﻌﻤﻞ اﻟﻘﻮﻣﻰ اﻟﺼﺤﻰ ﻣﻌﻬﺪ اﻻﻣﺮاض - ﺟﺎﻣﻌﺔ اﻟﺨﺮﻃﻮم 
و    اﻟﻤﻘﺎوﻣﺔ ﻟﻠﻌﻼجاﻟﺘﻌﺪد اﻟﺠﺰﻳﺌﻲ ﻟﻌﺘﺮات اﻟﺴﻞ ﻓﻰ ﺑﺤﺚ  اﻟﻤﺸﺎرآﺔاﻟﻤﻮاﻓﻘﺔ ﻋﻠﻲ  ﻤﺎرةاﺳﺘ
 ﻓﻰ ﺑﻌﺾ اﻗﺎﻟﻴﻢ اﻟﺴﻮدانﻟﻬﺎ ﻋﻤﻞ ﺧﺎرﻃﺔ ﺟﻴﻨﻴﺔ 
ﻳﻌﺘﻤﺪ ﺗﺸﺨﻴﺺ ﻣﺮض . اﻟﺮﺋﺘﻴﻦ ﺑﻈﻬﺮ ﻓﻲ ﺷﻜﻞ آﺤﺔ ﻋﺎدة ﻳﺼﻴﺐ( اﻟﺼﺪرﻳﺔ)ﻣﺮض اﻟﺪرن 
 اﻟﺘﺸﺨﻴﺺ اﻟﺤﺎﻟﻲ ﻻﻳﺴﺘﻄﻴﻊ .اﻟﻤﻴﻜﺮوب ﻓﻲ اﻟﺘﻔﺎف واﻷﺷﻌﺔ اﻟﺼﺪرﻳﺔ ﺣﺎﻟﻴﺎ ﻋﻠﻰ اآﺘﺸﺎف
اﻟﺘﻌﺮف ﻋﻠﻰ اﻟﻜﺜﻴﺮ ﻣﻨﻮ وﺣﺎﻟﻴﺎ أﺻﺒﺢ اﻟﻤﻴﻜﺮوب ﺑﻘﺎوم ﻋﻼج اﻟﺼﺪرﻳﺔ وﻋﺸﺎن ﻧﻜﺘﺸﻒ دﻩ 
 ﻧﺤﻦ .وآﻤﺎن ﻧﻮع اﻟﻤﻴﻜﺮوب اﻟﻤﻮﺟﻮد ﻋﻨﺪﻧﺎ هﻨﺎ ﻓﻰ اﻟﺴﻮدان ﺑﻴﺤﺘﺎج اﻟﻰ ﻣﻌﺎﻣﻞ ﻣﺠﻬﺰة
ﺟﺎﻣﻌﺔ /اﻟﺒﺎﺣﺜﻴﻦ واﻟﺪآﺎﺗﺮة ﺷﻐﺎﻟﻴﻦ ﻓﻰ اﻟﻤﻌﻤﻞ اﻟﻘﻮﻣﻰ اﻟﺼﺤﻰ و ﻣﻌﻬﺪ اﻻﻣﺮاض اﻟﻤﺘﻮﻃﻨﺔ
ﻟﻠﻌﻼج وﻣﻌﺮﻓﺔ اﻻﻧﻮاع ( اﻟﺪرن)ﺤﺚ ﻟﻤﻌﺮﻓﺔ ﻣﻘﺎوﻣﺔ اﻟﺼﺪرﻳﺔ ﺑﺎﺟﺮاء ﺑ ﺑﻨﻘﻮم . اﻟﺨﺮﻃﻮم
 . اﻟﻤﻮﺟﻮدة ﻓﻰ اﻟﺴﻮدان ﻋﻨﺪ ﻣﺮﺿﻰ اﻟﺼﺪرﻳﺔ
ﺣﻨﻘﻮم ﻧﺤﻦ ﺑﻔﺤﺺ اﻟﻠﻌﺎب ﻋﺸﺎن ﻧﺸﻮف . ﻋﻠﻰ اﻟﻤﺸﺎرآﺔ ﺣﻨﺎﺧﺬ ﻣﻨﻚ ﻋﻴﻨﺔ ﻟﻌﺎب ﻟﻮ واﻓﻘﺖ
ﻟﻮ ﺷﻔﻨﺎ اﻟﺼﺪرﻳﺔ ﺣﻨﻜﻠﻤﻚ . ﻋﺸﺎن ﺗﻘﻮم وﻧﻌﺮﻓﻬﺎ اﻟﺼﺪرﻳﺔ وﺣﻨﻘﻮم ﻧﺰرﻋﻬﺎ ﻓﻰ ﻣﻮاد هﻼﻣﻴﺔ
وﻓﻰ . ﻋﺸﺎن ﻳﺪوك اﻟﻌﻼج ﻣﺠﺎﻧﻰ وﻳﺘﺎﺑﻌﻮا ﺣﺎﻟﺘﻚ( اﻟﺪرن)ﻟﻨﺎس ﺑﺮﻧﺎﻣﺞ اﻟﺼﺪرﻳﺔ وﻧﺤﻮﻟﻚ 
ﺣﺎﻟﺔ ﻟﻘﻴﻨﺎك ﻣﻘﺎوم ﻟﻠﻌﻼج ﺣﻨﺴﺎﻋﺪك ﻋﺸﺎن ﺗﻠﻘﻰ اﻟﻌﻼج اﻟﺘﺎﻧﻰ ﺑﺮﺿﻮ ﺣﻨﺎﺧﺬ ﻣﻨﻚ ﻣﻌﻠﻮﻣﺎت 
آﻞ . وﻓﺘﺮة اﻟﻤﺮض و ﺷﻮﻳﺔ ﻣﻌﻠﻮﻣﺎت ﻓﻰ اﻻﺳﺘﺒﻴﺎن ﻋﻦ اﺳﻤﻚ وﻋﻤﺮك وﻋﻨﻮان ﺳﻜﻨﻚ
زول ﻏﻴﺮ اﻟﺒﺎﺣﺚ  ﻧﺎ وﺣﻨﺪﻳﻬﺎ ﻧﻤﺮ ﺳﺮﻳﺔ ﻣﺎﻓﻰاﻟﻤﻌﻠﻮﻣﺎت دى ﺣﺘﻜﻮن ﺳﺮﻳﺔ وﻣﺤﻔﻮﻇﺔ ﻋﻨﺪ
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اﻟﻌﻴﻨﺎت ﺣﻨﺴﺘﻌﻤﻠﻬﺎ ﻋﻨﺪﻧﺎ ﻓﻰ اﻟﻤﻌﻤﻞ اﻟﻘﻮﻣﻰ اﻟﺼﺤﻰ و . اﻻﺳﺎﺳﻴﻦ واﻟﺪآﺎﺗﺮة ﺣﻴﻌﺮﻓﻮهﺎ
ﺟﺎﻣﻌﺔ اﻟﺨﺮﻃﻮم ﺣﻨﺴﺘﻌﻤﻞ اﻟﻌﻴﻨﺎت وﻧﺤﻠﻠﻬﺎ ﻋﺸﺎن ﻧﺤﺎول ﻧﻌﺮف ﻣﻘﺎوﻣﺔ اﻟﺼﺪرﻳﺔ   ﻓﻰ اﻟﻤﻌﻬﺪ
وﺗﻄﻮﻳﺮ ﻋﻼﺟﺎت ﺟﺪﻳﺪة و  ﻤﻞﻟﻠﻌﻼج واﻻﻧﻮاع اﻟﻌﻨﺪﻧﺎ هﻨﺎ ﻓﻲ اﻟﺴﻮدان ودا ﻣﻤﻜﻦ ﻳﺴﺎﻋﺪ ﻓﻰ ﻋ
دى ﺣﻨﺴﺘﻌﻤﻠﻬﺎ  اﻟﻌﻴﻨﺎت. آﺎن وﺻﻠﻨﺎ ﻻى ﻧﺘﺎﺋﺞ ﺣﻨﻮرﻳﻚ اﻟﺤﺎﺻﻞ. ﻣﻜﺎﻓﺤﺔ ﻣﺮض اﻟﺼﺪرﻳﺔ 
ﺑﻘﻴﺔ اﻟﻌﻴﻨﺎت . ﻣﻮاﻓﻘﺘﻚ ﺑﺲ ﻓﻰ اﻟﺒﺤﺚ دا وﻟﻮ ﻋﺎﻳﺰﻳﻦ ﻧﺴﺘﻌﻤﻠﻬﺎ ﻓﻰ اى ﺑﺤﺚ ﺗﺎﻧﻰ ﻻزم ﻧﺎﺧﺬ
 .وﺣﺘﻜﻮن ﻋﻠﻴﻬﺎارﻗﺎم ﺳﺮﻳﺔ ﻋﻨﺪﻧﺎ ﺑﺪون ﻣﺎﻧﻜﺘﺐ اﻻﺳﻤﺎء ﻋﻠﻴﻬﺎ ﺣﻨﺨﺰﻧﻬﺎ
ﺣﻮاﻓﺰ ﻣﺎﻟﻴﺔ وﻣﺸﺎرآﺘﻚ ﻃﻮﻋﻴﺔ وﻣﻤﻜﻦ  ﻋﻠﻰ اﻟﻤﺸﺎرآﺔ ﻓﻰ اﻟﺒﺤﺚ ﻣﺎ ﺣﻨﺪﻳﻚ اى ﻟﻮ واﻓﻘﺖ
ﻣﺎﺣﻴﺆﺛﺮ ﻓﻰ ﺣﻘﻮﻗﻚ ﻓﻰ اﻟﻌﻼج او اﻟﺮﻋﺎﻳﺔ  ﺗﻄﻠﻊ ﻣﻦ اﻟﺒﺤﺚ ﻓﻰ ﻟﺤﻈﺔ اذا اردت ودا اﺑﺪا
اى ﺳﺆال ﻣﻤﻜﻦ ﺗﺴﺎل هﺴﻊ او ﺗﺴﺎل دآﺘﻮر ﻣﻮﺳﻰ  اذا آﺎن ﻋﻨﺪك. اﻟﻄﺒﻴﺔ او اى ﺣﻘﻮق ﺛﺎﻧﻴﺔ
 .اﻟﺨﺮﻃﻮم ﻓﻰ اى وﻗﺖ ﻣﺤﻤﺪ ﺧﻴﺮ ﻓﻰ ﻗﺴﻢ اﻟﺒﺎﻃﻨﻴﺔ ﻣﺴﺘﺸﻔﻰ
 
اﻟﻤﻌﻠﻮﻣﺎت ﻋﻦ ﻣﺸﺎرآﺘﻰ ﻓﻰ  ﻗﺮوا ﻟﻰ/ ﻗﺮﻳﺖ................................................... أﻧﺎ 
 .اﻟﻤﺸﺎرآﺔ ﻓﻰ اﻟﺒﺤﺚ اﻟﺒﺤﺚ وﻓﻬﻤﺘﻬﺎ وﺟﺎوﺑﻮا ﻟﻰ ﻋﻦ اﺳﺌﻠﺘﻰ وﻣﻮاﻓﻖ ﻋﻠﻰ
 .............................................اﻟﺸﺎهﺪ......................... اﻟﺒﺼﻤﺔ/ اﻻﻣﻀﺎء
 ................................اﻻﻣﻀﺎء...............................ﻣﻘﺪم اﻻﺳﺘﺒﻴﺎن  اﺳﻢ
  ..................................اﻟﺘﺎرﻳﺦ
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   Translate of the consent form 
 Molecular Diversity of drug resistance patterns of   Mycobacterium 
tuberculosis isolates from   different regions of Sudan 
 
TB patients consent form 
  We are researchers/ doctors working in the Institute of endemic 
diseases, University of Khartoum and National Health Laboratory. We 
are conducting a research study to make Map of drug resistance 
patterns of   Mycobacterium tuberculosis isolates from   different 
regions of Sudan. 
   You have been diagnosed with Sadria and the sputum test 
confirmed the presence of Sadria micrope. We would like to get your 
permission to participate in our study mapping of drug resistance 
patterns of   Mycobacterium tuberculosis isolates from   different 
regions of Sudan. 
  The Sadria diseases will be determined by seeing the Sadria 
microbe using machine called microscopy and by growing the Sadria 
in some liquids and gels (LJ culture media). We will inform you about 
the confirmation of the diseases and we will then send you to the 
national TB control programme in the ministry of Health for telling 
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the patients about the ways to follow for treatment. The patient will be 
given free treatment under medical observation. And if we detect that 
you infected with resistant strain we will help you to find the 
treatment. 
  We will take sputum in a container and we will also collect base 
line data of your name, age, disease and duration of disease. 
  All data will be kept in the computers, given secret number 
(code) and will not be available to anybody except us (investigators, 
and doctors). 
  We will use the samples in our laboratories in the Institute and 
National Health Laboratory. We will try to map the drug resistance 
patterns of   Mycobacterium tuberculosis in Sudan, If we succeed we 
will tell you of the result of the work (study) after it’s completion 
using the description of your home address. We will not use the 
samples in any other study without your agreement. We will keep the 
remaining parts of the samples for two years after the completion of 
the research. The samples will be stored without names and only with 
secret numbers (codes).  
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  You will not get any payment to participate in this study and 
your participation is completely up to you (voluntary) and you could 
leave the study at any time. If you decide not to participate or you 
drop out of the study this will not affect your right for treatment and 
medical assistance. You can consult Dr. Musa M. Kheir, (Doctor of 
Medicine) in Khartoum hospital for any inquiry or complain related to 
this study. 
I-----------------------------------, “I have read the foregoing information, 
or it has been read to me. 
   I have had the opportunity to ask questions about it and any 
questions I have asked have been answered to my satisfaction. I 
consent voluntarily to participate as a subject in this study and 
understand that I have the right to withdraw from the study at any 
time without in any way it affecting my further medical care .  
Witness ------------------------------------------ Date ------------------------ 
Administered by.---------------------------- 
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Appendix 4 
Ziehl-Neelsen stain: 
Carbol fuchsin was prepared by mixing 10 mL of basic fuchsin in 
90 mL of phenl solution.  
Basic fuchsin was prepared by dissolving of 3.0 g  in 100 ml of 95% 
ethanol. 
Phenol solution was prepared by dissolving of 5 g of phenol 
crystals in 100 mL distilled water, It was placed in water bath to 
ensure complete dissolving. 
Acid alcohol was prepared by mixing 30 ml of concentrated 
hydrochloric acid with 970 ml of 95% ethanol. 
 Methylene blue was prepared by dissolving of 3 g of methylene 
blue chloride in 1000 ml of distilled water. 
3. Catalase reagents: 
1. Buffer solution 0.067 M, pH 7.0 (mixture of 0.067 M sodium 
hydrogen phosphate and 0.067 M potassium dihydrogen phosphate). 
2. Tween peroxide (10% Tween 80 and 30% H2O2 (autoclaved). 
4. Nitrate test: 
1. Nitrate buffer; Sodiun nitrate substrate in water. 
2. Hydrochloric acid solution. 
3. Sulfanilamide solution, 0.2% 
4. N-nephthylethylene-diamine solution, 01%. 
5. Tellurite reduction 
Tellurite (potassium Tellurite 0.2g +100ml sterile distilled water). 
 
